WO2016209921A1 - Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors - Google Patents

Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors Download PDF

Info

Publication number
WO2016209921A1
WO2016209921A1 PCT/US2016/038702 US2016038702W WO2016209921A1 WO 2016209921 A1 WO2016209921 A1 WO 2016209921A1 US 2016038702 W US2016038702 W US 2016038702W WO 2016209921 A1 WO2016209921 A1 WO 2016209921A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
cells
cell
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/038702
Other languages
French (fr)
Inventor
Parul DORSHI
Henk M. LOKHORST
Tuna MUTIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2017566284A priority Critical patent/JP6816038B2/en
Priority to CR20170587A priority patent/CR20170587A/en
Priority to EA201890093A priority patent/EA036789B1/en
Priority to MYPI2017704912A priority patent/MY192978A/en
Priority to UAA201800576A priority patent/UA125115C2/en
Priority to ES16815196T priority patent/ES2890783T3/en
Priority to HK18110269.3A priority patent/HK1250666B/en
Priority to NZ738208A priority patent/NZ738208B2/en
Priority to IL256242A priority patent/IL256242B2/en
Priority to CN201680037051.9A priority patent/CN107708734B/en
Priority to EP16815196.7A priority patent/EP3310386B1/en
Priority to CA2990406A priority patent/CA2990406A1/en
Priority to PH1/2017/502342A priority patent/PH12017502342B1/en
Priority to MX2018000265A priority patent/MX391068B/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority to AU2016282674A priority patent/AU2016282674B2/en
Priority to KR1020187001610A priority patent/KR102601550B1/en
Priority to BR112017027724A priority patent/BR112017027724A2/en
Priority to HK18110389.8A priority patent/HK1250928B/en
Priority to TW105134915A priority patent/TWI724046B/en
Publication of WO2016209921A1 publication Critical patent/WO2016209921A1/en
Priority to CONC2017/0013331A priority patent/CO2017013331A2/en
Anticipated expiration legal-status Critical
Priority to ZA2018/00403A priority patent/ZA201800403B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Definitions

  • the present invention relates to combination treatments for heme malignancies. BACKGROUND OF THE INVENTION
  • MM Multiple Myeloma
  • MM is a B cell malignancy characterized by the latent accumulation of secretory plasma cells in bone marrow with a low proliferative index and an extended life span. The disease ultimately attacks bones and bone marrow, resulting in multiple tumors and lesions throughout the skeletal system. Approximately 1% of all cancers, and slightly more than 10% of all hematologic malignancies, can be attributed to MM. Incidence of MM increases in the aging population, with the median age at time of diagnosis being about 61 years.
  • MM Currently available therapies for MM include chemotherapy regimens, stem cell transplantation, THALOMID® (thalidomide), REVLIMID® (lenalidomide),
  • POMALYST® (pomalidomide), VELCADE® (bortezomib), KYPROLIS® (carfilzomib), FARADYK® (panobinostat), AREDIA® (pamidronate), and ZOMETA® (zoledronic acid).
  • Current treatment protocols which include a combination of chemotherapeutic agents such as vincristine, BCNU, melphalan, cyclophosphamide, adriamycin, and prednisone or dexamethasone, yield a complete remission rate of only about 5%, and median survival is approximately 36-48 months from the time of diagnosis.
  • Efficacy of the available drug treatment regimens for MM is limited by the low cell proliferation rate and development of drug resistance in up to 90% of patients.
  • BM bone marrow
  • CD38 a type II transmembrane glycoprotein is an attractive target for antibody therapeutics for various heme malignancies, including multiple myeloma.
  • Anti-CD38 antibodies are described, for example, in Intl. Pat. Publ. No. WO2008/037257, Intl. Pat. Publ. No. WO2008/047242 and Intl. Pat. Publ. No. WO2007/042309, and are being evaluated in clinical settings for their efficacy in multiple myeloma and other heme malignancies.
  • the invention provides for a method of treating a subject having a CD38-positive hematological malignancy, comprising administering to the subject in need thereof an anti- CD38 antibody and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy.
  • FIG. 1A Bone Marrow stromal cells (BMSCs) mediate protection against multiple myeloma (MM) cell killing by ADCC induced by anti-CD38 antibody daratumumab in MM cell lines.
  • BMSCs bone Marrow stromal cells
  • Luciferase transduced CD38 + UM9 MM cells were cultured in the presence or absence of healthy donor BMSCs (HD-BMSCs) for 16 hours prior to incubation with serial concentrations of daratumumab and HD-PBMCs at a PBMC:MM cell ratio of 30:1.
  • MM cell viability was determined after 4 hours by bioluminescence imaging (BLI). Percent (%) ADCC was calculated relative to the cell viability without daratumumab.
  • BMSCs Bone Marrow stromal cells
  • MM multiple myeloma
  • Luciferase transduced CD38 + RPMI8226 MM cells were cultured in the presence or absence of HD-BMSCs for 16 hours prior to incubation with serial concentrations of daratumumab and HD-PBMCs at a PBMC:MM cell ratio of 30:1.
  • Figure 2A BMSCs mediate protection against MM cell killing by ADCC induced by anti-CD38 antibody daratumumab in primary MM patient samples. Full Bone marrow aspirates obtained from MM patient 1 was cultured in the presence (white bars) or absence (black bars) of autologous bone marrow stromal cells and then treated with daratumumab at indicated concentrations.
  • BM-MNCs already contain NK cells as effector cells, no additional effector cells were added.
  • FIG. 2B BMSCs mediate protection against MM cell killing by ADCC induced by anti- CD38 antibody daratumumab in primary MM patient samples.
  • Full Bone marrow aspirates obtained from MM patient 2 was cultured in the presence (white bars) or absence (black bars) of autologous bone marrow stromal cells and then treated with daratumumab at indicated concentrations. The autologous cells present in aspirate were used as effector cells. Since BM-MNCs already contain NK cells as effector cells, no additional effector cells were added. The viability of CD138 + MM cells in the cultures was determined after 24 hours by flow cytometry. Error bars indicate the SEM of triplicate measurements.
  • YM155 does not induce NK cell lysis.
  • HD-PBMCs and patient bone marrow mononuclear cells (BMMNCs) were incubated with the indicated concentrations of YM155 for 24 hours.
  • the number of viable CD3- CD56 + NK cells was determined by flow cytometry and the percent lysis was calculated using the untreated samples as negative control.
  • FIG. 4A Daratumumab in combination with YM155 provide synergistic effect on MM cell killing by ADCC in the presence of stromal cells. Luciferase transduced RPMI8226 MM cells were cultured in presence or absence of HD-BMSCs. Daratumumab and YM155 were added at the indicated concentrations. HD-PBMCs were added in all wells at a PBMC:MM ratio of 40:1 as a source of NK cells to induce ADCC. RPMI8226 cell survival was determined after 4 hours by BLI. The % lysis was calculated relative to the survival of RPMI8226 cells that did not receive any treatment. In the case of the YM155 and daratumumab combination, the expected lysis values were deduced from
  • FIG. 4B Daratumumab in combination with YM155 provides synergistic effect on primary MM cell killing by ADCC in the presence of stromal cells.
  • Full BM aspirates of the MM patient 1 were cultured in the presence or absence of autologous MM-BMSCs.
  • Daratumumab and YM155 were added at the indicated concentrations. Since BM-MNCs contain sufficient NK cells (in both cases, approximately at a 30:1 NK: MM cell ratio), no additional effector cells were added. After 24 hours, the viable CD138 + MM cells were enumerated in each condition via flow cytometry.
  • Figure 4C Daratumumab in combination with YM155 provides synergistic effect on primary MM cell killing by ADCC in the presence of stromal cells. Full BM aspirates of the MM patient 2 were cultured in the presence or absence of autologous MM-BMSCs. Daratumumab and YM155 were added at the indicated concentrations.
  • Figure 4D Daratumumab in combination with YM155 provides synergistic effect on primary MM cell killing by ADCC in the presence of stromal cells.
  • Bone marrow mononuclear cells from four MM patients containing CD138 + MM cells (45%, 5.5% 10.2% 21.6% for patient 1-4, respectively) were cultured in the presence or absence of autologous MM-BMSCs.
  • Daratumumab (1 ng/ml) and appropriate sub maximal concentrations of YM155 (125, 62, 75 and 50 ng/ml for patient 1-4, respectively) were added.
  • BM-MNCs contained sufficient NK cells (7.9%, 7.9%, 10.3% and 9.5% respectively), no additional effector cells were added.
  • the viable CD138 + MM cells were enumerated in each condition via flow cytometry.
  • mice received T cell depleted HD-PBMCs (5x10 6 cells) as a source of human NK cells to induce ADCC. Mice were monitored weekly by BLI. Results are expressed as the mean tumor load in each scaffold. The error bars represent the SEM. The statistical differences between mice treated with daratumumab and mice treated with daratumumab plus YM155 were calculated using the Mann-Whitney U-test.
  • CD38 refers to the human CD38 protein (synonyms: ADP-ribosyl cyclase 1, cADPr hydrolase 1, cyclic ADP-ribose hydrolase 1).
  • Human CD38 has an amino acid sequence as shown in SEQ ID NO: 1. It is well known that CD38 is a single pass type II membrane protein with amino acid residues 1-21 representing the cytosolic domain, amino acid residues 22-42 representing the transmembrane domain, and residues 43-300 representing the extracellular domain of CD38.
  • antibodies as used herein is meant in a broad sense and includes immunoglobulin molecules including, monoclonal antibodies including murine, human, human-adapted, humanized and chimeric monoclonal antibodies, antibody fragments, bispecific or multispecific antibodies, dimeric, tetrameric or multimeric antibodies, and single chain antibodies.
  • Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence.
  • IgA and IgG are further sub-classified as the isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4.
  • Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda based on the amino acid sequences of
  • antibody fragments refers to a portion of an immunoglobulin molecule that retains the heavy chain and/or the light chain antigen binding site, such as heavy chain complementarity determining regions (HCDR) 1, 2 and 3, light chain complementarity determining regions (LCDR) 1, 2 and 3, a heavy chain variable region (VH), or a light chain variable region (VL).
  • HCDR heavy chain complementarity determining regions
  • LCDR light chain complementarity determining regions
  • VH heavy chain variable region
  • VL light chain variable region
  • Antibody fragments include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; a F(ab) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CHI domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a domain antibody (dAb) fragment (Ward et al., Nature 341:544- 546, 1989), which consists of a VH domain.
  • VH and VL domains can be engineered and linked together via a synthetic linker to form various types of single chain antibody designs where the VH/VL domains pair intramolecularly, or
  • isolated antibody refers to an antibody or antibody fragment that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody specifically binding CD38 is substantially free of antibodies that specifically bind antigens other than human CD38).
  • An isolated antibody that specifically binds CD38 can have cross-reactivity to other antigens, such as orthologs of human CD38, such as Macaca fascicularis (cynomolgus) CD38.
  • an isolated antibody may be substantially free of other cellular material and/or chemicals.
  • An antibody variable region consists of a“framework” region interrupted by three “antigen binding sites”.
  • the antigen binding sites are defined using various terms: (i) Complementarity Determining Regions (CDRs), three in the VH (HCDR1, HCDR2, HCDR3), and three in the VL (LCDR1, LCDR2, LCDR3) are based on sequence variability (Wu and Kabat J Exp Med 132:211-50, 1970; Kabat et al Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991).
  • CDRs Complementarity Determining Regions
  • HCDR1, HCDR2, HCDR3 three in the VH
  • LCDR1, LCDR2, LCDR3 three in the VL
  • sequence variability Wu and Kabat J Exp Med 132:211-50, 1970; Kabat et al Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991).
  • Framework or“framework sequences” are the remaining sequences of a variable region other than those defined to be antigen binding sites. Because the antigen binding sites can be defined by various terms as described above, the exact amino acid sequence of a framework depends on how the antigen-binding site was defined.
  • Humanized antibody refers to an antibody in which the antigen binding sites are derived from non-human species and the variable region frameworks are derived from human immunoglobulin sequences. Humanized antibodies may include substitutions in the framework regions so that the framework may not be an exact copy of expressed human immunoglobulin or germline gene sequences.
  • Human antibody refers to an antibody having heavy and light chain variable regions in which both the framework and the antigen binding sites are derived from sequences of human origin. If the antibody contains a constant region, the constant region also is derived from sequences of human origin.
  • a human antibody comprises heavy or light chain variable regions that are “derived from” sequences of human origin if the variable regions of the antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes.
  • Such systems include human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice carrying human immunoglobulin loci as described herein.“Human antibody” may contain amino acid differences when compared to the human germline or rearranged immunoglobulin sequences due to for example naturally occurring somatic mutations or intentional introduction of substitutions in the framework or antigen binding sites.
  • a “human antibody” is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical in amino acid sequence to an amino acid sequence encoded by a human germline or rearranged immunoglobulin gene.
  • a“human antibody” may contain consensus framework sequences derived from human framework sequence analyses, for example as described in Knappik et al., J Mol Biol 296:57-86, 2000), or synthetic HCDR3 incorporated into human immunoglobulin gene libraries displayed on phage, as described in, for example, Shi et al., J Mol Biol 397:385-96, 2010 and Intl. Pat. Publ. No.
  • Antibodies in which antigen binding sites are derived from a non- human species are not included in the definition of“human antibody”.
  • Isolated humanized antibodies may be synthetic.
  • Human antibodies, while derived from human immunoglobulin sequences, may be generated using systems such as phage display incorporating synthetic CDRs and/or synthetic frameworks, or can be subjected to in vitro mutagenesis to improve antibody properties, resulting in antibodies that do not naturally exist within the human antibody germline repertoire in vivo.
  • Recombinant antibody includes all antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described further below), antibodies isolated from a host cell transformed to express the antibody, antibodies isolated from a recombinant, combinatorial antibody library, and antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences, or antibodies that are generated in vitro using Fab arm exchange.
  • an animal e.g., a mouse
  • transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom described further below
  • antibodies isolated from a host cell transformed to express the antibody antibodies isolated from a recombinant, combinatorial antibody library, and antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequence
  • “Monoclonal antibody” refers to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope, or in a case of a bispecific monoclonal antibody, a dual binding specificity to two distinct epitopes.
  • “Monoclonal antibody” therefore refers to an antibody population with single amino acid composition in each heavy and each light chain, except for possible well known alterations such as removal of C-terminal lysine from the antibody heavy chain.
  • Monoclonal antibodies may have heterogeneous glycosylation within the antibody population.
  • Monoclonal antibody may be monospecific or multispecific, or monovalent, bivalent or multivalent. A bispecific antibody is included in the term monoclonal antibody.
  • Epitope refers to a portion of an antigen to which an antibody specifically binds.
  • Epitopes usually consist of chemically active (such as polar, non-polar or hydrophobic) surface groupings of moieties such as amino acids or polysaccharide side chains and can have specific three-dimensional structural characteristics, as well as specific charge characteristics.
  • An epitope can be composed of contiguous and/or discontiguous amino acids that form a conformational spatial unit. For a discontiguous epitope, amino acids from differing portions of the linear sequence of the antigen come in close proximity in 3- dimensional space through the folding of the protein molecule.
  • Variant refers to a polypeptide or a polynucleotide that differs from a reference polypeptide or a reference polynucleotide by one or more modifications for example, substitutions, insertions or deletions.
  • “In combination with” means that two or more therapeutics can be administered to a subject together in a mixture, concurrently as single agents or sequentially as single agents in any order.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development or spread of a tumor or tumor cells.
  • Beneficial or desired clinical results include alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable and prolonging survival as compared to expected survival if not receiving treatment.
  • Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
  • “Therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result.
  • a therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response in the individual.
  • Exemplary indicators of an effective therapeutic or combination of therapeutics that may decline or abate in association with resistance include, for example, improved well-being of the patient, reduction of a tumor burden, arrested or slowed growth of a tumor, and/or absence of metastasis of cancer cells to other locations in the body.
  • “Synergy”,“synergism” or“synergistic” mean more than the expected additive effect of a combination.
  • “Inhibits growth” refers to a measurable decrease in the cell growth in vitro or in vivo when contacted with a therapeutic or a combination or therapeutics or drugs when compared to the growth of the same cells grown in appropriate control conditions well known to the skilled in the art. Inhibition of growth of a cell in vitro or in vivo may be at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. Inhibition of cell growth can occur by a variety of mechanisms, for example by ADCC, apoptosis, necrosis, or by inhibition of cell proliferation.
  • Subject includes any human or nonhuman animal.“Nonhuman animal” includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows chickens, amphibians, reptiles, etc. The terms“subject” and“patient” are used interchangeably herein.
  • “Survivin” as used herein refers to the survivin protein having the amino acid sequence shown in SEQ ID NO: 22.
  • Survivin is a member of the inhibitor of apoptosis (IAP) family.
  • Survivin is a dual functional protein acting as an apoptosis inhibitor and cell cycle regulator. Overexpression of survivin is observed in human malignancies and positively correlates with poor prognosis, tumor recurrence, and therapeutic resistance (Liu et al., Cancer Biol. Ther., 7:1053-1060, 2008; Mita et al., Clin Cancer Res., 14:5000- 5005, 2008).
  • “Survivin inhibitor” refers to a molecule that inhibits, antagonizes, reduces or suppresses survivin activity; e.g., a molecule that inhibits the anti-apoptotic activity of survivin in a cell.
  • Survivin inhibitor may inhibit the anti-apoptotic activity of survivin by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%.
  • Survivin inhibitors may be a small molecule, peptide, a vaccine, a polynucleotide, DNA or RNA molecule.
  • the present invention is based, at least in part, on the finding that bone marrow stromal cells (BMSC) residing in the BM niche protect MM cells against antibody-induced ADCC at least in part by upregulating survivin, and that survivin inhibitors improve antibody-mediated ADCC of MM cells and abrogate ADCC resistance induced by BMSCs.
  • BMSCs have been shown to protect MM cells from cytotoxic T-lymphocyte (CTL)-dependent lysis via cell adhesion-mediated immune resistance, and survivin has been found to be upregulated in the lysis-resistant MM cells (de Haart et al., Clin Cance Res 19:5591-5601, 2013).
  • the invention provides for a method of treating a subject having a CD38-positive hematological malignancy, comprising administering to the subject in need thereof an anti- CD38 antibody and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy.
  • the invention also provides for a method of inhibiting growth or proliferation of multiple myeloma cells in a subject, comprising administering an anti-CD38 antibody and a survivin inhibitor to the subject in need thereof for a time sufficient to inhibit growth or proliferation of multiple myeloma cells.
  • CD38-positive hematological malignancy refers to a hematological malignancy characterized by the presence of tumor cells expressing CD38, including leukemias, lymphomas and myeloma.
  • exemplary such CD38-positive hematological malignancies are precursor B-cell lymphoblastic leukemia/lymphoma and B-cell non-Hodgkin's lymphoma, acute promyelocytic leukemia, acute lymphoblastic leukemia and mature B- cell neoplasms, such as B-cell chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), B-cell acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL), including low-grade, intermediate- grade and high-grade FL, cutaneous follicle center lymphoma, marginal zone
  • lymphoproliferative disorder Waldenstrom's macroglobulinemia, plasma cell leukemias and anaplastic large-cell lymphoma (ALCL).
  • ACL anaplastic large-cell lymphoma
  • CD38 is expressed in a variety of malignant hematological diseases, including multiple myeloma, leukemias and lymphomas, such as B-cell chronic lymphocytic leukemia, T- and B-cell acute lymphocytic leukemia, Waldenstrom’s macroglobulinemia, primary systemic amyloidosis, mantle-cell lymphoma, pro-lymphocytic/myelocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, follicular lymphoma, Burkitt’s lymphoma, large granular lymphocytic (LGL) leukemia, NK-cell leukemia and plasma-cell leukemia.
  • multiple myeloma such as B-cell chronic lymphocytic leukemia, T- and B-cell acute lymphocytic leukemia, Waldenstrom’s macroglobulinemia, primary systemic amyloidosis, mantle-cell lymphoma, pro-
  • CD38 has been described on epithelial/endothelial cells of different origin, including glandular epithelium in prostate, islet cells in pancreas, ductal epithelium in glands, including parotid gland, bronchial epithelial cells, cells in testis and ovary and tumor epithelium in colorectal adenocarcinoma.
  • CD38 expression could be involved include, e.g., broncho-epithelial carcinomas of the lung, breast cancer (evolving from malignant proliferation of epithelial lining in ducts and lobules of the breast), pancreatic tumors, evolving from the E-cells (insulinomas), tumors evolving from epithelium in the gut (e.g. adenocarcinoma and squamous cell carcinoma), carcinoma in the prostate gland, and seminomas in testis and ovarian cancers.
  • neuroblastomas express CD38.
  • the CD38-positive hematological malignancy is multiple myeloma (MM), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
  • MM multiple myeloma
  • ALL acute lymphoblastic leukemia
  • NHL non-Hodgkin's lymphoma
  • DLBCL diffuse large B-cell lymphoma
  • FL follicular lymphoma
  • MCL mantle-cell lymphoma
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • the CD38-positive hematological malignancy is MM.
  • the CD38-positive hematological malignancy is ALL.
  • the CD38-positive hematological malignancy is NHL.
  • the CD38-positive hematological malignancy is DLBCL. In some embodiments, the CD38-positive hematological malignancy is BL.
  • the CD38-positive hematological malignancy is FL.
  • the CD38-positive hematological malignancy is MCL. In some embodiments, the CD38-positive hematological malignancy is AML. In some embodiments, the CD38-positive hematological malignancy is CLL.
  • the CD38-positive hematological malignancy is a plasma cell disease.
  • the plasma cell disease is light chain amyloidosis (AL), multiple myeloma (MM) or Waldenstrom’s macroglobulinemia.
  • AL light chain amyloidosis
  • MM multiple myeloma
  • Waldenstrom Waldenstrom’s macroglobulinemia.
  • the plasma cell disease is AL.
  • the plasma cell disease is MM.
  • the plasma cell disease is Waldenstrom’s
  • B-cell non-Hodgkin's lymphomas are lymphomatoid granulomatosis, primary effusion lymphoma, intravascular large B-cell lymphoma, mediastinal large B-cell lymphoma, heavy chain diseases (including ⁇ , ⁇ , and a disease), lymphomas induced by therapy with immunosuppressive agents, such as cyclosporine-induced lymphoma, and methotrexate-induced lymphoma.
  • the disorder involving cells expressing CD38 is Hodgkin's lymphoma.
  • disorders involving cells expressing CD38 include malignancies derived from T and NK cells including mature T cell and NK cell neoplasms including T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T-cell leukemia/lymphoma, extranodal NK/T cell lymphoma, nasal type, 78 enteropathy-type T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, blastic NK cell lymphoma, Mycosis Fungoides/Sezary Syndrome, primary cutaneous CD30 positive T-cell lymphoproliferative disorders (primary cutaneous anaplastic large cell lymphoma C- ALCL, lymphomatoid papulosis, borderline lesions), angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma unspecified, and ana
  • malignancies derived from myeloid cells include acute myeloid leukemia, including acute promyelocytic leukemia, and chronic myeloproliferative diseases, including chronic myeloid leukemia.
  • variable regions of the anti-CD38 antibodies may be obtained from existing anti-CD38 antibodies and optionally cloned as full length antibodies using standard methods.
  • Exemplary antibody variable regions binding CD38 that may be used are described for example in Intl. Pat. Publ. Nos. WO05/103083, WO06/125640, WO07/042309, WO08/047242, WO12/092612, WO06/099875, and WO11/154453A1.
  • An exemplary anti-CD38 antibody that may be used is DARZALEX TM
  • DARZALEX TM (daratumumab) comprises a heavy chain variable region (VH) and a light chain variable region (VL) amino acid sequences as shown in SEQ ID NO: 4 and 5, respectively, a heavy chain complementarity determining region (HCDR) 1, a HCDR2 and a HCDR3 amino acid sequences as shown in SEQ ID NOs: 6, 7 and 8, respectively, and a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 amino acid sequences as shown in SEQ ID NOs: 9, 10 and 11, respectively, and is of IgG1/N subtype.
  • DARZALEX TM (daratumumab) heavy chain amino acid sequence is shown in SEQ ID NO: 12 and light chain amino acid sequence shown in SEQ ID NO: 13.
  • Another exemplary anti-CD38 antibody that may be used is mAb003 comprising the VH and VL sequences of SEQ ID NOs: 14 and 15, respectively and described in U.S. Pat. No.7,829,693.
  • SEQ ID NO: 14 is a sequence of SEQ ID NOs: 14 and 15, respectively and described in U.S. Pat. No.7,829,693.
  • SEQ ID NO: 14 is a sequence of SEQ ID NOs: 14 and 15, respectively and described in U.S. Pat. No.7,829,693.
  • mAb024 comprising the VH and VL sequences of SEQ ID NOs: 16 and 17, respectively and described in U.S. Pat. No.7,829,693.
  • MOR-202 (MOR- 03087) comprising the VH and VL sequences of SEQ ID NOs: 18 and 19, respectively and described in US. Pat. No.8,088,896.
  • isatuximab comprising the VH and VL sequences of SEQ ID NOs: 20 and 21, respectively, described in U.S. Pat. No.8,153,765.
  • the VH and the VL of isatuximab may be expressed as IgG1/N.
  • Anti-CD38 antibodies used in the methods of the invention may also be selected de novo from for example a phage display library, where the phage is engineered to express human immunoglobulins or portions thereof such as Fabs, single chain antibodies (scFv), or unpaired or paired antibody variable regions (Knappik et al., J Mol Biol 296:57- 86, 2000; Krebs et al., J Immunol Meth 254:67-84, 2001; Vaughan et al., Nature Biotechnology 14:309-314, 1996; Sheets et al., PITAS (USA) 95:6157-6162, 1998;
  • CD38 binding variable domains may be isolated for example from phage display libraries expressing antibody heavy and light chain variable regions as fusion proteins with bacteriophage pIX coat protein as described in Shi et al (2010) J. Mol. Biol.397:385-96 and Intl. Pat. Publ. No. WO09/085462).
  • the antibody libraries may be screened for binding to human CD38 extracellular domain and the obtained positive clones may be further characterized and the Fabs isolated from the clone lysates, and subsequently cloned as full length antibodies.
  • the invention also provides for a method of treating a subject having a CD38- positive hematological malignancy, comprising administering to the subject in need thereof an anti-CD38 antibody that competes for binding to CD38 with an antibody comprising the VL of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy.
  • the invention also provides for a method of treating a subject having multiple myeloma, comprising administering to the subject in need thereof an anti-CD38 antibody that competes for binding to CD38 with an antibody comprising the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 and a survivin inhibitor for a time sufficient to treat multiple myeloma.
  • the invention also provides for a method of treating a subject having a CD38- positive hematological malignancy, comprising administering to the subject in need thereof an anti-CD38 antibody that binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy.
  • the invention also provides for a method of treating a subject having multiple myeloma, comprising administering to the subject in need thereof an anti-CD38 antibody that binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region
  • EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1).and a survivin inhibitor for a time sufficient to treat multiple myeloma.
  • the anti-CD38 antibody comprises the HCDR1, the HCDR2 and hte HCDR2 of SEQ ID NOs: 6, 7 and 8, respectively.
  • the anti-CD38 antibody comprises the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 9, 10 and 11, respectively.
  • the anti-CD38 antibody comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively.
  • the anti-CD38 antibody comprises the VL comprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 4 and the VL omprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 5.
  • the anti-CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5.
  • the anti-CD38 antibody comprises the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 15.
  • the anti-CD38 antibody comprises the VH of SEQ ID NO: 16 and the VL of SEQ ID NO: 17
  • the anti-CD38 antibody comprises the VH of SEQ ID NO: 18 and the VL of SEQ ID NO: 19.
  • the anti-CD38 antibody comprises the VH of SEQ ID NO: 20 and the VL of SEQ ID NO: 21.
  • Antibodies may be evaluated for their competition with a reference antibody, for example DARZALEX TM (daratumumab having the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 for binding to CD38 using well known in vitro methods.
  • CHO cells recombinantly expressing CD38 may be incubated with unlabeled reference antibody for 15 min at 4qC, followed by incubation with an excess of fluorescently labeled test antibody for 45 min at 4qC. After washing in PBS/BSA, fluorescence may be measured by flow cytometry using standard methods.
  • extracellular portion of human CD38 may be coated on the surface of an ELISA plate.
  • Excess of unlabelled reference antibody may be added for about 15 minutes and subsequently biotinylated test antibodies may be added. After washes in PBS/Tween, binding of the test biotinylated antibody may be detected using horseradish peroxidase (HRP)-conjugated streptavidin and the signal detected using standard methods.
  • HRP horseradish peroxidase
  • the reference antibody may be labeled and the test antibody unlabeled.
  • the test antibody competes with the reference antibody when the reference antibody inhibits binding of the test antibody, or the test antibody inhibits binding of the reference antibody by at least 80%, 85%, 90% , 95% or 100%.
  • the epitope of the test antibody may further be defined for example by peptide mapping or hydrogen/deuterium protection assays using known methods, or by crystal structure determination.
  • an anti-CD38 antibody binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) when the antibody binds at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 residues within SEQ ID NO: 2 and SEQ ID NO: 3.
  • the anti-CD38 antibody binds at least one amino acid in the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and at least one amino acid in the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1).
  • the anti-CD38 antibody binds at least two amino acids in the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and at least two amino acids in the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1). In some embodiments, the anti-CD38 antibody binds at least three amino acids in the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and at least three amino acids in the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1).
  • An exemplary antibody that binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) is DARZALEX TM (daratumumab).
  • Antibodies binding to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) may be generated for example by immunizing mice with peptides having the amino acid sequences shown in SEQ ID NOs: 2 and 3 using standard methods and as described herein, and characterizing the obtained antibodies for binding to the peptides using for example ELISA or mutagenesis studies.
  • the Fc portion of the antibody may mediate antibody effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) or complement dependent cytotoxicity (CDC), as described in more detail below.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • CDC complement dependent cytotoxicity
  • Such functions may be mediated by binding of an Fc effector domain(s) to an Fc receptor on an immune cell with phagocytic or lytic activity or by binding of an Fc effector domain(s) to components of the complement system.
  • the effect(s) mediated by the Fc-binding cells or complement components result in inhibition and/or depletion of target cells, e.g., CD38-expressing cells.
  • ADCC may be mediated by IgG1 and IgG3
  • ADCP may be mediated by IgG1, IgG2, IgG3 and IgG4
  • CDC may be mediated by IgG1 and IgG3.
  • the anti-CD38 antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.
  • the anti-CD38 antibody is of IgG1 isotype.
  • the anti-CD38 antibody is of IgG2 isotype.
  • the anti-CD38 antibody is of IgG3 isotype.
  • the anti-CD38 antibody is of IgG4 isotype.
  • the anti-CD38 antibody induces killing of CD38- expressing cells by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or apoptosis.
  • ADCC antibody-dependent cellular cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • CDC complement-dependent cytotoxicity
  • the anti-CD38 antibody induces killing of CD38- expressing cells by ADCC.
  • the anti-CD38 antibody induces killing of CD38- expressing cells by ADCP.
  • the anti-CD38 antibody induces killing of CD38-expressing cells by CDC. In some embodiments, the anti-CD38 antibody induces killing of CD38- expressing cells by apoptosis.
  • Antibody-dependent cellular cytotoxicity is a mechanism for inducing cell death that depends upon the interaction of antibody-coated target cells with effector cells possessing lytic activity, such as natural killer cells, monocytes, macrophages and neutrophils via Fc gamma receptors (FcJR) expressed on effector cells.
  • effector cells possessing lytic activity such as natural killer cells, monocytes, macrophages and neutrophils via Fc gamma receptors (FcJR) expressed on effector cells.
  • FcJR Fc gamma receptors
  • NK cells express FcJRIIIa
  • monocytes express FcJRI, FcJRII and FcJRIIIa.
  • Death of the antibody-coated target cell such as CD38-expressing MM cell, occurs as a result of effector cell activity through the secretion of membrane pore-forming proteins and proteases.
  • the antibody may be added to CD38-expressing cells in combination with immune effector cells, which may be activated by the antigen antibody complexes resulting in cytolysis of the target cell. Cytolysis may be detected by the release of label (e.g., radioactive substrates, fluorescent dyes or natural intracellular proteins) from the lysed cells.
  • label e.g., radioactive substrates, fluorescent dyes or natural intracellular proteins
  • exemplary effector cells for such assays include peripheral blood mononuclear cells (PBMC) and NK cells.
  • PBMC peripheral blood mononuclear cells
  • NK cells multiple myeloma cell lines or primary MM cells that express CD38 may be used as target cells.
  • MM cell lines engineered to express luciferase are incubated with anti-CD38 antibodies.
  • complement receptors e.g., CR3
  • primary BM- MNC cells isolated from a patient with a B-cell malignancy may be treated with an anti- CD38 antibody and complement derived from 10% pooled human serum for 1 hour at a concentration of 0.3-10 ⁇ g/ml, and the survival of primary CD138 + MM cells may be determined by flow cytometry using techniques described in van der Veer et al., Haematologica 96:284-290, 2011; van der Veer et al., Blood Cancer J 1(10):e41, 2011. The percentage of MM cell lysis may be determined relative to an isotype control as described herein.
  • Anti-CD38 antibodies used in the methods of the invention may induce CDC by about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%
  • ADCP Antibody-dependent cellular phagocytosis
  • phagocytic cells such as macrophages or dendritic cells.
  • ADCP may be evaluated by using monocyte-derived macrophages as effector cells and Daudi cells (ATCC ® CCL-213 TM ) or B cell leukemia or lymphoma tumor cells expressing CD38 as target cells engineered to express GFP or other labeled molecule. Effector:target cell ratio may be, for example, 4:1. Effector cells may be incubated with target cells for 4 hours with or without anti-CD38 antibody. After incubation, cells may be detached using accutase.
  • Macrophages may be identified with anti-CD11b and anti-CD14 antibodies coupled to a fluorescent label, and percent phagocytosis may be determined based on % GFP fluorescent in the CD11 + CD14 + macrophages using standard methods.
  • Anti-CD38 antibodies used in the methods of the invention may induce ADCP by about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% .
  • ADCC elicited by anti-CD38 antibodies may be enhanced by certain substitutions in the antibody Fc.
  • Exemplary substitutions are for example substitutions at amino acid positions 256, 290, 298, 312, 356, 330, 333, 334, 360, 378 or 430 (residue numbering according to the EU index) as described in U.S. Pat. No.6,737,056.
  • the anti-CD38 antibodies comprise an amino acid substitution in the antibody Fc.
  • the anti-CD38 antibodies comprise a substitution in the antibody Fc at amino acid positions 256, 290, 298, 312, 356, 330, 333, 334, 360, 378 or 430 (residue numbering according to the EU index).
  • ADCC elicted by anti-CD38 antibodies can also be enhanced by engineering the antibody oligosaccharide component.
  • Human IgG1 or IgG3 are N-glycosylated at Asn297 with the majority of the glycans in the biantennary G0, G0F, G1, G1F, G2 or G2F forms.
  • Antibodies produced by non-engineered CHO cells typically have a glycan fucose content of about at least 85%. The removal of the core fucose from the biantennary complex-type oligosaccharides attached to the Fc regions enhances the ADCC of antibodies via improved Fc ⁇ RIIIa binding without altering antigen binding or CDC activity.
  • Such modified antibodies can be achieved using different methods reported to lead to the successful expression of relatively high defucosylated antibodies bearing the biantennary complex-type of Fc oligosaccharides such as control of culture osmolality (Konno et al., Cytotechnology 64(:249-65, 2012), application of a variant CHO line Lec13 as the host cell line (Shields et al., J Biol Chem 277:26733-26740, 2002), application of a variant CHO line EB66 as the host cell line (Olivier et al., MAbs ;2(4), 2010; Epub ahead of print; PMID:20562582), application of a rat hybridoma cell line YB2/0 as the host cell line (Shinkawa et al., J Biol Chem 278:3466-3473, 2003), introduction of small interfering RNA specifically against the D 1,6-fucosyltrasferase ( FUT8) gene (Mori
  • the anti-CD38 antibody has a biantennary glycan structure with fucose content between about 0% to about 15%, for example 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%.
  • the anti-CD38 antibody has a biantennary glycan structure with fucose content of about 50%, 40%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%
  • “Fucose content” means the amount of the fucose monosaccharide within the sugar chain at Asn297.
  • the relative amount of fucose is the percentage of fucose- containing structures related to all glycostructures. These may be characterized and quantified by multiple methods, for example: 1) using MALDI-TOF of N-glycosidase F treated sample (e.g. complex, hybrid and oligo- and high-mannose structures) as described in Int Pat. Publ. No.
  • the oligosaccharides thus released can be labeled with a fluorophore, separated and identified by various complementary techniques which allow: fine characterization of the glycan structures by matrix-assisted laser desorption ionization (MALDI) mass spectrometry by comparison of the experimental masses with the theoretical masses, determination of the degree of sialylation by ion exchange HPLC (GlycoSep C), separation and quantification of the oligosacharride forms according to hydrophilicity criteria by normal-phase HPLC (GlycoSep N), and separation and quantification of the oligosaccharides by high performance capillary electrophoresis- laser induced fluorescence (HPCE-LIF).
  • MALDI matrix-assisted laser desorption ionization
  • Low fucose or“low fucose content” as used in the application refers to antibodies with fucose content of about 0% to about15%.
  • Normal fucose or‘normal fucose content” as used herein refers to antibodies with fucose content of about over 50%, typically about over 80% or over 85%.
  • Antibodies that are substantially identical to the antibody comprising the heavy chain of SEQ ID NO: 12 and the light chain of SEQ ID NO: 13 may be used in the methods of the invention.
  • the term“substantially identical” as used herein means that the two antibody heavy chain or light chain amino acid sequences being compared are identical or have“insubstantial differences”. Insubstantial differences are substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in an antibody heavy chain or light chain that do not adversely affect antibody properties. Percent identity can be determined for example by pairwise alignment using the default settings of the AlignX module of Vector NTI v.9.0.0 (Invitrogen, Carlsbad, CA).
  • the protein sequences of the present invention can be used as a query sequence to perform a search against public or patent databases to, for example, identify related sequences. Exemplary programs used to perform such searches are the XBLAST or BLASTP programs
  • substitutions that can be made to the anti- CD38 antibodies used in the methods of the invention are for example conservative substitutions with an amino acid having similar charge, hydrophobic, or stereochemical characteristics. Conservative substitutions may also be made to improve antibody properties, for example stability or affinity, or to improve antibody effector functions. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions may be made, for example, to the heavy or the light chain of the anti-CD38 antibody.
  • any native residue in the heavy or light chain may also be substituted with alanine, as has been previously described for alanine scanning mutagenesis (MacLennan et al., Acta Physiol Scand Suppl 643:55-67, 1998; Sasaki et al., Adv Biophys 35:1-24, 1998). Desired amino acid substitutions may be determined by those skilled in the art at the time such substitutions are desired. Amino acid substitutions may be done for example by PCR mutagenesis (U.S. Pat. No.4,683,195).
  • variants may be generated using well-known methods, for example using random (NNK) or non-random codons, for example DVK codons, which encode 11 amino acids (Ala, Cys, Asp, Glu, Gly, Lys, Asn, Arg, Ser, Tyr, Trp) and screening the libraries for variants with desired properties.
  • the generated variants may be tested for their binding to CD38 and their ability to induce ADCC using methods described herein.
  • Constant modifications refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequences.
  • Conservative modifications include amino acid substitutions, additions and deletions.
  • Conservative substitutions are those in which the amino acid is replaced with an amino acid residue having a similar side chain.
  • amino acids with acidic side chains e.g., aspartic acid, glutamic acid
  • basic side chains e.g., lysine, arginine, histidine
  • nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine
  • uncharged polar side chains e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine, tryptophan
  • aromatic side chains e.g., phenylalanine, tryptophan, histidine, tyrosine
  • aliphatic side chains e.g., glycine, alanine, valine, leucine, isoleucine, serine, threonine
  • amide e.g., asparagine, glutamine
  • beta- branched side chains e.g., asparagine
  • any native residue in the polypeptide may also be substituted with alanine, as has been previously described for alanine scanning mutagenesis (MacLennan et al., (1988) Acta Physiol Scand Suppl 643:55-67; Sasaki et al., (1988) Adv Biophys 35:1-24).
  • Amino acid substitutions to the antibodies of the invention may be made by known methods for example by PCR mutagenesis (US Patent No.
  • libraries of variants may be generated for example using random (NNK) or non-random codons, for example DVK codons, which encode 11 amino acids (Ala, Cys, Asp, Glu, Gly, Lys, Asn, Arg, Ser, Tyr, Trp).
  • NNK random
  • DVK codons which encode 11 amino acids (Ala, Cys, Asp, Glu, Gly, Lys, Asn, Arg, Ser, Tyr, Trp).
  • the resulting antibody variants may be tested for their characteristics using assays described herein.
  • the anti-CD38 antibody may bind human CD38 with a range of affinities (K D ).
  • the anti-CD38 antibody binds to CD38 with a K D equal to or less than about 1x10 -8 M, for example 5x10 -9 M, 1x10 -9 M, 5x10 -10 M, 1x10 -10 M, 5x10 -11 M, 1x10 -11 M, 5x10 -12 M, 1x10 -12 M, 5x10 -13 M, 1x10 -13 M, 5x10 -14 M, 1x10 -14 M or 5x10 -15 M, or any range or value therein, as determined by surface plasmon resonance or the Kinexa method, as practiced by those of skill in the art.
  • An exemplary affinity is equal to or less than 1x10 -8 M.
  • Another exemplary affinity is equal to or less than 1x10 -9 M.
  • KinExA instrumentation ELISA or competitive binding assays known to those skilled in the art.
  • the measured affinity of a particular antibody/ CD38 interaction may vary if measured under different conditions (e.g., osmolarity, pH).
  • affinity and other binding parameters e.g., K D , K on , K off
  • K D , K on , K off are typically made with standardized conditions and a standardized buffer, such as the buffer described herein.
  • the internal error for affinity measurements for example using Biacore 3000 or ProteOn (measured as standard deviation, SD) may typically be within 5-33% for measurements within the typical limits of detection.
  • K D ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
  • the anti-CD38 antibody is a bispecific antibody.
  • the VL and/or the VH regions of existing anti-CD38 antibodies or the VL and VH regions identified de novo as described herein may be engineered into bispecific full length antibodies.
  • Such bispecific antibodies may be made by modulating the CH3 interactions in antibody Fc to form bispecific antibodies using technologies such as those described in U.S. Pat. No.7,695,936; Int. Pat. Publ. No. WO04/111233; U.S. Pat. Publ. No.
  • bispecific antibodies of the invention may be generated in vitro in a cell-free environment by introducing asymmetrical mutations in the CH3 regions of two monospecific homodimeric antibodies and forming the bispecific heterodimeric antibody from two parent monospecific homodimeric antibodies in reducing conditions to allow disulfide bond isomerization according to methods described in Intl.Pat. Publ. No.
  • the first monospecific bivalent antibody e.g., anti- CD38 antibody
  • the second monospecific bivalent antibody are engineered to have certain substitutions at the CH3 domain that promote heterodimer stability; the antibodies are incubated together under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide bond isomerization; thereby generating the bispecific antibody by Fab arm exchange.
  • the incubation conditions may optimally be restored to non-reducing.
  • Exemplary reducing agents that may be used are 2- mercaptoethylamine (2- MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2- carboxyethyl)phosphine (TCEP), L-cysteine and beta-mercaptoethanol, preferably a reducing agent selected from the group consisting of: 2- mercaptoethylamine, dithiothreitol and tris(2-carboxyethyl)phosphine.
  • incubation for at least 90 min at a temperature of at least 20°C in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM dithiothreitol at a pH of from 5-8, for example at pH of 7.0 or at pH of 7.4 may be used.
  • Exemplary CH3 mutations that may be used in a first heavy chain and in a second heavy chain of the bispecific antibody are K409R and/or F405L.
  • VL and/or the VH regions of the antibodies of the invention are for example Dual Variable Domain Immunoglobulins (DVD) (Int. Pat. Publ. No. WO2009/134776), or structures that include various dimerization domains to connect the two antibody arms with different specificity, such as leucine zipper or collagen dimerization domains (Int. Pat. Publ. No.
  • DVD Dual Variable Domain Immunoglobulins
  • dimerization domains to connect the two antibody arms with different specificity, such as leucine zipper or collagen dimerization domains
  • DVDs are full length antibodies comprising the heavy chain having a structure VH1-linker-VH2-CH and the light chain having the structure VL1-linker-VL2-CL; linker being optional.
  • the anti-CD38 antibody is conjugated to a toxin.
  • the subject having MM is homozygous for phenylalanine at position 158 of CD16 (FcJRIIIa-158F/F genotype) or heterozygous for valine and pheynylalanine at position 158 of CD16 (FcJRIIIa-158F/V genotype).
  • CD16 is also known as the Fc gamma receptor IIIa (FcJRIIIa) or the low affinity immunoglobulin gamma Fc region receptor III-A isoform.
  • Valine/phenylalanine (V/F) polymorphism at FcJRIIIa protein residue position 158 has been shown to affect FcJRIIIa affinity to human IgG.
  • Receptor with FcJRIIIa-158F/F or FcJRIIIa-158F/V polymorphisms demonstrates reduced Fc engagement and therefore reduced ADCC when compared to the FcJRIIIa- 158V/V.
  • the lack of or low amount of fucose on human N-linked oligosaccharides improves the ability of the antibodies to induce ADCC due to improved binding of the antibodies to human FcJRIIIa (CD16) (Shields et al., J Biol Chem 277:26733-40, 2002).
  • Patients can be analyzed for their FcJRIIIa polymorphism using routine methods.
  • the survivin inhibitor is a small molecule.
  • the survivin inhibitor is a polynucleotide.
  • Survivin inhibitors may inhibit survivin-induced apoptosis by any mechanism, such as inhibiting survivin gene transcription or protein expression, inhibiting survivin protein dimerization, enhancing destabilization or inducing its degradation, etc.
  • An exemplary survivin small molecule inhibitor is YM155.
  • YM155 binds to the survivin promoter and inhibits its transcription.
  • Other exemplary survivin small molecule inhibitors are, for example, nordihydroguaiaretic acid derivatives as described in U.S. Pat. No.6,608,108, and molecules described in U.S. Pat. Publ. No. US2012/0122910.
  • Other survivin polynucleotide inhibitors are described, for example, in U.S. Pat. No.6,838,283, Intl. Pat. Publ Nos. WO01/057059, WO09/114476 and WO09/044793.
  • Polynucleotide inhibitors include microRNAs (miRNAs), small intereference RNAs (siRNAs), allele specific oligos (ASOs) and other polynucleotide inhibitors know in the art.
  • miRNAs microRNAs
  • siRNAs small intereference RNAs
  • ASOs allele specific oligos
  • the anti-CD38 antibodies may be provided in suitable pharmaceutical compositions comprising the anti-CD38 antibody and a pharmaceutically acceptable carrier.
  • the carrier may be diluent, adjuvant, excipient, or vehicle with which the anti-CD38 antibody is administered.
  • vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. For example, 0.4% saline and 0.3% glycine can be used. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration).
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, thickening, lubricating and coloring agents, etc.
  • concentration of the molecules or antibodies of the invention in such pharmaceutical formulation may vary widely, i.e., from less than about 0.5%, usually to at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the particular mode of administration selected.
  • Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin are described, for example, in e.g. Remington: The Science and Practice of Pharmacy, 21 st Edition, Troy, D.B.
  • the mode of administration of the anti-CD38 antibody in the methods of the invention may be any suitable route such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal) or other means appreciated by the skilled artisan, as well known in the art.
  • parenteral administration e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal) or other means appreciated by the skilled artisan, as well known in the art.
  • the anti-CD38 antibody in the methods of the invention may be may administered to a patient by any suitable route, for example parentally by intravenous (IV) infusion or bolus injection, intramuscularly or subcutaneously or intraperitoneally.
  • IV infusion can be given over for example 15, 30, 60, 90, 120, 180, or 240 minutes, or from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours.
  • the dose given to a patient having CD38-positive hematological malignancy is sufficient to alleviate or at least partially arrest the disease being treated (“therapeutically effective amount”) and may be sometimes 0.005 mg to about 100 mg/kg, e.g. about 0.05 mg to about 30 mg/kg or about 5 mg to about 25 mg/kg, or about 4 mg/kg, about 8 mg/kg, about 16 mg/kg or about 24 mg/kg , or for example about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg/kg, but may even higher, for example about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90 or 100 mg/kg.
  • a fixed unit dose may also be given, for example, 50, 100, 200, 500 or 1000 mg, or the dose may be based on the patient's surface area, e.g., 500, 400, 300, 250, 200, or 100 mg/m 2 .
  • 1 and 8 doses e.g., 1, 2, 3, 4, 5, 6, 7 or 8
  • the administration of the anti-CD38 antibody in the methods of the invention may be repeated after one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months or longer. Repeated courses of treatment are also possible, as is chronic administration.
  • the repeated administration may be at the same dose or at a different dose.
  • the anti-CD38 antibody in the methods of the invention may be administered at 8 mg/ kg or at 16 mg/kg at weekly interval for 8 weeks, followed by administration at 8 mg/ kg or at 16 mg/kg every two weeks for an additional 16 weeks, followed by administration at 8 mg/ kg or at 16 mg/kg every four weeks by intravenous infusion.
  • the anti-CD38 antibodies may be administered in the methods of the invention by maintenance therapy, such as, e.g.,. once a week for a period of 6 months or more.
  • anti-CD38 antibodies in the methods of the invention may be provided as a daily dosage in an amount of about 0.1-100 mg/kg, such as 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one of day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively, at least one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 after initiation of treatment, or any combination thereof, using single or divided doses of every 24, 12, 8, 6, 4, or 2 hours, or any combination thereof.
  • Anti-CD38 antibodies in the methods of the invention may also be administered prophylactically in order to reduce the risk of developing cancer, delay the onset of the occurrence of an event in cancer progression, and/or reduce the risk of recurrence when a cancer is in remission. This may be especially useful in patients wherein it is difficult to locate a tumor that is known to be present due to other biological factors.
  • the anti-CD38 antibody in the methods of the invention may be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional protein preparations and well known lyophilization and reconstitution techniques can be employed.
  • the anti-CD38 antibody is administered in combination with a survivin inhibitor.
  • the anti-CD38 antibody is administered in combination with a survivin inhibitor YM155.
  • YM155 used in the methods of the invention is readily available according to the processes of production as disclosed in International Publication Intl. Pat. Publ. Nos. WO01/60803 and WO2004/092160.
  • YM155 may be administered orally or parenterally, or intravenously.
  • the injection preparation for intravenous administration includes those containing sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • the aqueous solvent includes, for example, distilled water for injection and physiological saline.
  • the non-aqueous solvent includes, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80, and the like.
  • Such compositions may contain further tonicity adjusting agents, antiseptics, moistening agents, emulsifying agents, dispersing agents, stabilizers, and solubilizing agents.
  • YM155 may be administered, for example, at 0.1- 20 mg/m 2 /day, such as at 1-10 mg/m 2 /day, once a day or divided in plural doses, or continuously by infusion (continuous instillation).
  • YM155 may be infused at 3-10 mg/m 2 /day continuously for a period of 4 days to 20 days, for example 4 days to 14 days, or 5 days, 7 days, 10 days or 14 days, and or for 7 days.
  • a medication cycle may be employed comprising a term of drug holidays of 1 day to 2 months, 7 days to 21 days, or 14 days, after termination of the above term of medication.
  • YM155 may be administered continuously by infusion at a dose of 3-8 mg/m2/day for 7 days, followed by drug holidays of 14 days; this cycle as one cycle is repeated depending on the conditions.
  • the frequency of administration, dosage, time of infusion, medication cycle, and the like may be determined properly according to individual cases considering the kind of anticancer agent, state of the patients, age, gender, etc.
  • the combination of the anti-CD38 antibody and survivin inhibitor may be administered over any convenient timeframe.
  • the anti-CD38 antibody and survivin inhibitor may be administered to a patient on the same day.
  • the anti-CD38 antibody and survivin may also be administered on alternating days or alternating weeks or months, and so on.
  • the anti- CD38 antibody and survivin inhibitor may be administered with sufficient proximity in time that they are simultaneously present (e.g., in the serum) at detectable levels in the patient being treated.
  • an entire course of treatment with the anti-CD38 antibody consisting of a number of doses over a time period is followed or preceded by a course of treatment with survivin inhibitor, consisting of a number of doses.
  • a recovery period of 1, 2 or several days or weeks may be used between administration of the anti- CD38 antibody and survivin inhibitor.
  • Anti-CD38 antibody in combination with survivin inhibitor may be administered together with any form of radiation therapy including external beam radiation, intensity modulated radiation therapy (IMRT) and any form of radiosurgery including Gamma Knife, Cyberknife, Linac, and interstitial radiation (e.g., implanted radioactive seeds, GliaSite balloon), and/or with surgery.
  • IMRT intensity modulated radiation therapy
  • radiosurgery including Gamma Knife, Cyberknife, Linac, and interstitial radiation (e.g., implanted radioactive seeds, GliaSite balloon), and/or with surgery.
  • Subcutaneous administration of pharmaceutical compositions comprising an antibody that specifically binds CD38 and a hyaluronidase
  • the anti-CD38 antibody may be administered as a pharmaceutical composition comprising the anti-CD38 antibody and a hyaluronidase subcutaneously.
  • the concentration of the anti-CD38 antibody in the pharmaceutical composition administered subcutaneously may be about 20 mg/ml.
  • the pharmaceutical composition administered subcutaneously may comprise between about 1,200 mg– 1,800 mg of the anti-CD38 antibody.
  • the pharmaceutical composition administered subcutaneously may comprise about 1,200 mg of the anti-CD38 antibody.
  • the pharmaceutical composition administered subcutaneously may comprise about 1,600 mg of the anti-CD38 antibody.
  • the pharmaceutical composition administered subcutaneously may comprise about 1,800 mg of the anti-CD38 antibody.
  • the pharmaceutical composition administered subcutaneously may comprise between about 30,000 U– 45,000 U of the hyaluronidase.
  • the pharmaceutical composition administered subcutaneously may comprise about 1,200 mg of the anti-CD38 antibody and about 30,000 U of the hyaluronidase.
  • the pharmaceutical composition administered subcutaneously may comprise about 1,800 mg of the anti-CD38 antibody and about 45,000 U of the hyaluronidase.
  • the pharmaceutical composition administered subcutaneously may comprise about 1,600 mg of the anti-CD38 antibody and about 30,000 U of the hyaluronidase.
  • the pharmaceutical composition administered subcutaneously may comprise about 1,600 mg of the anti-CD38 antibody and about 45,000 U of the hyaluronidase.
  • the pharmaceutical composition administered subcutaneously may comprise the hyaluronidase rHuPH20 having the amino acid sequence of SEQ ID NO: 23.
  • rHuPH20 is a recombinant hyaluronidase (HYLENEX® recombinant) and is described in Int. Pat. Publ. No. WO2004/078140.
  • Hyaluronidase is an enzyme that degrades hyaluronic acid (EC 3.2.1.35) and lowers the viscosity of hyaluronan in the extracellular matrix, thereby increasing tissue permeability.
  • SEQ ID NO: 23 is an enzyme that degrades hyaluronic acid (EC 3.2.1.35) and lowers the viscosity of hyaluronan in the extracellular matrix, thereby increasing tissue permeability.
  • the repeated administration may be at the same dose or at a different dose.
  • the pharmaceutical composition comprising the anti-CD38 antibody and the hyaluronidase may be administered once weekly for eight weeks, followed by once in two weeks for 16 weeks, followed by once in four weeks.
  • the pharmaceutical compositions to be administered may comprise about 1,200 mg of the anti-CD38 antibody and about 30,000 U of hyaluronidase, wherein the concentration of the antibody that specifically binds CD38 in the pharmaceutical composition is about 20 mg/ml.
  • the pharmaceutical compositions to be administered may comprise about 1,800 mg of the anti-CD38 antibody and about 45,000 U of hyaluronidase.
  • the pharmaceutical compositions to be administered may comprise about 1,600 mg of the anti-CD38 antibody and about 30,000 U of hyaluronidase.
  • the pharmaceutical compositions to be administered may comprise about 1,600 mg of the anti-CD38 antibody and about 45,000 U of hyaluronidase.
  • the pharmaceutical composition comprising the anti-CD38 antibody and the hyaluronidase may be administered subcutaneously to the abdominal region.
  • the pharmaceutical composition comprising the anti-CD38 antibody and the hyaluronidase may be administered in a total volume of about 80 ml, 90 ml, 100 ml, 110 ml or 120 ml.
  • CD38-positive hematological malignancy is multiple myeloma (MM), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
  • MM multiple myeloma
  • ALL acute lymphoblastic leukemia
  • NHL non-Hodgkin's lymphoma
  • DLBCL diffuse large B-cell lymphoma
  • BL Burkitt’s lymphoma
  • FL follicular lymphoma
  • MCL mantle-cell lymphoma
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • anti-CD38 antibody for use according to embodiment 1 or 4, the survivin inhibitor for use according to embodiment 2 or 4, or the combination according to embodiment 3 or 4, wherein CD38-positive hematological malignancy is a plasma cell disease.
  • the anti-CD38 antibody for use according to any one of embodiments 1 or 4-6, the survivin inhibitor for use according to any one of embodiments 2 or 4-6, or the combination according to any one of embodiments 3 or 4-6, wherein the plasma cell disease is MM.
  • anti-CD38 antibody for use according to any one of embodiments 1 or 4-7, the survivin inhibitor for use according to any one of embodiments 2 or 4-7, or the combination according to any one of embodiments 3 or 4-7, wherein the anti- CD38 antibody induces CD38-positive cell killing by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or apoptosis.
  • ADCC antibody-dependent cellular cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • CDC complement-dependent cytotoxicity
  • anti-CD38 antibody for use according to any one of embodiments 1 or 4-8, the survivin inhibitor for use according to any one of embodiments 2 or 4-8, or the combination according to any one of embodiments 3 or 4-8, wherein the anti- CD38 antibody is
  • IgG1, IgG2, IgG3 or IgG4 isotype
  • b. is of IgG1 isotype.
  • anti-CD38 antibody for use according to any one of embodiments 1 or 4-9, the survivin inhibitor for use according to any one of embodiments 2 or 4-9, or the combination according to any one of embodiments 3 or 4-9, wherein the anti- CD38 antibody
  • VH heavy chain variable region
  • VL light chain variable region
  • b. binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1);
  • c. comprises the heavy chain complementarity determining regions (HCDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) sequences of SEQ ID NOs: 6, 7 and 8, respectively;
  • d. comprises the light chain complementarity determining regions (LCDR) 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) sequences of SEQ ID NOs: 9, 10 and 11, respectively;
  • e. comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 sequences of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively;
  • VH heavy chain variable region
  • VL light chain variable region
  • g. comprises the heavy chain variable region (VH) of SEQ ID NO: 4 and the light chain variable region (VL) of SEQ ID NO: 5;
  • h. comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of:
  • anti-CD38 antibody for use according to any one of embodiments 1 or 4-10, the survivin inhibitor for use according to any one of embodiments 2 or 4-10, or the combination according to any one of embodiments 3 or 4-10, wherein the anti- CD38 antibody comprises the heavy chain variable region (VH) of SEQ ID NO: 4 and the light chain variable region (VL) of SEQ ID NO: 5.
  • the anti-CD38 antibody for use according to any one of embodiments 1 or 4-11, the survivin inhibitor for use according to any one of embodiments 2 or 4-11, or the combination according to any one of embodiments 3 or 4-11, wherein the survivin inhibitor is a small molecule, or a polynucleotide or a vaccine.
  • anti-CD38 antibody for use according to any one of embodiments 1 or 4-13, the survivin inhibitor for use according to any one of embodiments 2 or 4-13, or the combination according to any one of embodiments 3 or 4-13, wherein the anti- CD38 antibody and the survivin inhibitor are administered simultaneously, sequentially or separately.
  • An anti-CD38 antibody for use in treating a subject having a CD38-positive
  • the anti-CD38 antibody comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 sequences of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively; 16.
  • anti-CD38 antibody for use according to any one of embodiments 15-17, wherein the anti-CD38 antibody comprises a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13.
  • anti-CD38 antibody for use according to any one of embodiments 15-18, wherein the anti-CD38 antibody and the survivin inhibitor are administered simultaneously, sequentially or separately.
  • anti-CD38 antibody for use according to any one of embodiments 15-19, wherein the anti-CD38 antibody is administered subcutaneously in a
  • composition comprising the anti-CD38 antibody and a hyaluronidase.
  • hyaluronidase is rHuPH20 of SEQ ID NO: 23.
  • BM-MNCs Bone marrow mononuclear cells
  • PBMCs peripheral blood mononuclear cells
  • BM aspirates from MM patients or healthy individuals, as well as PB from healthy individuals were collected using protocols and procedures approved by the institutional medical ethical committee in accordance with the declaration of Helsinki.
  • Healthy Donor (HD)-PBMCs and BM-MNCs were isolated by Ficoll-Hypaque density-gradient centrifugation from PB samples or BM aspirates respectively.
  • PBMCs were used directly as effector cells in ADCC experiments; BM-MNCs were cryopreserved until use.
  • luciferase (Luc)-transduced human MM cell lines RPMI-8226 and UM9 were maintained in RPMI1640 (Invitrogen), supplemented with 10% fetal bovine serum (FBS; Integro BV) and antibiotics (penicillin/streptomycin; Life Technologies) at 37°C in a humidified atmosphere containing 5% CO 2 .
  • FBS fetal bovine serum
  • antibiotics penicillin/streptomycin; Life Technologies
  • Adherent stromal cells were isolated and cultured from BM-MNCs of healthy individuals (hBMSC) or of MM patients (pBMSC) by plastic adherence. Cells were cultured in Optimem (Invitrogen) with 5% platelet lysate, heparin and antibiotics.
  • hBMSCs were used in experiments until passage six and pBMSC were used after passage one or two. Reagents
  • YM155 (Sepantronium Bromide; 4,9-Dihydro-1-(2-methoxyethyl)-2-methyl-4,9- dioxo-3-(2-pyrazinylmethyl)-1H-naphth[2,3-d]imidazolium bromide; CAS 781661-94-7) (Selleck Chemicals) was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1mM and aliquoted for storage until use. YM155 was diluted in culture medium to the concentrations indicated in each experiment. YM155; Formula I:
  • hBMSC hBMSC were plated at a density of 1x10 4 cells/well in white opaque flat-bottomed 96-well plates (Costar) in 100 ⁇ l culture medium. After an adherence period of six hours, luc-transduced MM cell lines were added at a density of 1x10 4 cells/well in BMSC-coated or uncoated wells. In experiments in which YM155 was tested, YM155 was added at indicated concentrations together with MM cells. After 16-20 hours, daratumumab was added at indicated concentrations and left for 15 minutes at room temperature. Freshly isolated PBMC from healthy individuals were then added as effector cells at the indicated effector target ratios.
  • BM-MNCs Frozen BM-MNCs from MM patients with 15-35% CD138 + MM cells were used in FACS-based ADCC assays. The cells were thawed and cultured in 10% HS in RPMI. After 16-20 h, BM-MNCs were counted by trypan blue exclusion and 4x10 4 cells/well were plated in 96 round bottom plates. Daratumumab and/or YM155 were added in the wells as indicated per experiment.
  • the cells were additionally stained with CD105 as a marker for BMSCs.
  • the CD38 expression on CD105 negative cells was determined by FACS as described (de Haart et al., Clin Cancer Res 19:5591-601, 2013).
  • Hybrid scaffolds consisting of three 2- to 3-mm biphasic calcium phosphate particles coated with HD-BMSC were in vitro loaded with Luc + MM cell line UM9 (1x10 6 cells /scaffold) before s.c. implantation into RAG2 -/- ⁇ c -/- mice as described previously (Groen et al., Blood 120:e9-e16, 2012).
  • mice with tumors growing in the scaffolds were treated with vehicle control, daratumumab + PBS or daratumumab+ YM155.
  • Each mice, including the control group received in addition T cell-depleted HD-PBMCs (5x10 6 cells) as a source of human NK cells to induce ADCC.
  • T cell-depleted HD-PBMCs (5x10 6 cells) as a source of human NK cells to induce ADCC.
  • PBS and YM155-diluted in PBS were administered using ssubcutaneous infusion pumps (Alzet 1007D) delivering 1 mg/kg/d of the drug continuously. Pumps were removed after 10 days.
  • Example 1 Bone Marrow stromal cells confer protection against antibody- dependent cellular cytotoxicity of multiple myeloma cells
  • ADCC antibody-dependent cellular cytotoxicity
  • Figure 1A shows the effect of BMSCs on daratumumab-induced ADCC in UM9 cells
  • Figure 1B shows the effect of BMSCs on daratumumab-induced ADCC in RPMI-8226 cells.
  • BM-MNCs containing at least 15% CD138 + malignant plasma cells and sufficient numbers of autologous effector NK cells were incubated with daratumumab to induce ADCC.
  • the BM-MNCs were tested either alone or in co-culture with autologous BMSCs to evaluate the effect of BMSCs.
  • FACS-based viability assay was performed after 24 hours of culture to determine CD138 + surviving cells and calculate lysis.
  • MM cell lines UM9 and RPMI-8226 were cultured in the presence or absence of healthy donor BMSCs. Co-culture of MM cells with BMSCs did not down-regulate the CD38 expression levels on either MM cell line (data not shown).
  • BMSCs are known to produce several immunosuppressive factors such as IDO, TGF- ⁇ or PGE-2
  • the protection against ADCC by BMSCs could be due to the suppression of NK-cell activation, which would reduce their ability to degranulate and release granzyme B and perforin in the immune synapses to kill their targets.
  • effect of BMSCs on NK cell activation by daratumumab was determined using daratumumab-mediated granzyme B excretion as a marker for NK cell activity. Granzyme B levels were in general higher in the supernatants in the presence pf BMSCs (data not shown). Hence, BMSC-mediated protection against ADCC was likely not due to NK cell suppression.
  • Example 3 Survivin inhibition abrogates BMSC-mediated protection against ADCC and provides synergistic ADCC-mediated killing of multiple myeloma cells with daratumumab
  • BMSCs have been shown to protect MM cells against CTL lysis by up-regulation of survivin in MM cells. Modulation of survivin was evaluated as a possible mechanism for BMSC-mediated protection against ADCC induced by daratumumab using YM155, a small molecule inhibitor of survivin.
  • BM-MNCs of MM patients were cultured in the presence of different doses of YM155 for 24 hours.
  • Viability of MM cells (CD138 + cells) and NK cells (CD3-CD138-CD56 + cells) were determined by FACS. NK cells were not affected at YM155 doses which already showed some toxicity to MM cells ( Figure 3).
  • daratumumab and YM155 were used at a concentration of 0.3 ⁇ g/ml and 1 nM, respectively, for RPMI-8226 cells and at a concentration of 1 ⁇ g/ml and 120 nM for MM patient samples, respectively.
  • Healthy donor PBMCs were used as effector cells at effector:target cell ratio of 40:1 for RPMI-8226 cells and 30:1 for MM patient samples.
  • daratumumab alone or YM155 alone induced lysis of about 20% of cells in the absence of BMSCs.
  • daratumumab induced lysis of about 10% of cells, whereas YM155 had no effect.
  • Combination of daratumumab and YM155 provided a synergistic effect inducing lysis of about 50% of cells in the absence of BMSCs, and inducing lysis of about 45% of cells in the presence of BMSCs ( Figure 4A).
  • the synergistic effect of the combination of daratumumab and YM155 in the BMSCs was about 5-fold.
  • daratumumab and YM155 provided a synergistic effect in the MM patient sample 1 using 120 nM YM155 (Figure 4B), a moderate synergistic effect in the MM patient sample 2 using a lower amount of YM155 (64 nM) ( Figure 4C), and in a combined sample of MM cells derived from 4 patients ( Figure 4D).
  • YM155 therefore abrogated the protective effects of BMSCs on daratumumab-mediated ADCC in MM cells and cell lines.
  • survivin up-regulation may be an important mechanism of suppression of ADCC-mediated killing of MM cells, which can be prevented by pharmacological modulation of survivin.
  • Example 4 In vivo antitumor effect of daratumumab and YM155 combination therapy
  • YM155 or its vehicle, PBS was delivered with subcutaneous infusion pumps at a rate of 1 mg/kg/d YM155 for 10 days.
  • Figure 5 shows the relative tumor growth for each group.
  • Statistical differences between mice treated with daratumumab and mice treated with daratumumab plus YM155 were calculated using the Mann-Whitney U-test.
  • YM155 to daratumumab demonstrated enhanced antitumor effects also in the absence of BMSCs, which suggest the potential benefits of YM155-daratumumab combination therapy even if the MM cells are not in direct contact with BMSCs, such as in plasma cell leukemia.
  • ADCC significant improvement of ADCC, up to a four-fold improvement of MM cell lysis, in the presence of BMSCs, suggests that a larger benefit from combining daratumumab therapy with YM155 can be achieved for MM cells which reside in the BM. It was also demonstrated that YM155 treatment does not negatively interfere with NK cell functions or viability, which is a prerequisite to consider clinical application of this combination therapy.
  • AML is an eminent candidate, since AML cells not only express high levels of CD38, but also high levels of survivin, which is a predictor for poor clinical outcome.
  • Another potential candidate for combination therapy might be CLL, since CLL cells have high survivin expression in the BM and CD38 is expressed in some patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.

Description

COMBINATION THERAPIES FOR HEME MALIGNANCIES WITH ANTI-CD38 ANTIBODIES AND SURVIVIN INHIBITORS
FIELD OF THE INVENTION
The present invention relates to combination treatments for heme malignancies. BACKGROUND OF THE INVENTION
Multiple Myeloma (MM) is a B cell malignancy characterized by the latent accumulation of secretory plasma cells in bone marrow with a low proliferative index and an extended life span. The disease ultimately attacks bones and bone marrow, resulting in multiple tumors and lesions throughout the skeletal system. Approximately 1% of all cancers, and slightly more than 10% of all hematologic malignancies, can be attributed to MM. Incidence of MM increases in the aging population, with the median age at time of diagnosis being about 61 years.
Currently available therapies for MM include chemotherapy regimens, stem cell transplantation, THALOMID® (thalidomide), REVLIMID® (lenalidomide),
POMALYST® (pomalidomide), VELCADE® (bortezomib), KYPROLIS® (carfilzomib), FARADYK® (panobinostat), AREDIA® (pamidronate), and ZOMETA® (zoledronic acid). Current treatment protocols, which include a combination of chemotherapeutic agents such as vincristine, BCNU, melphalan, cyclophosphamide, adriamycin, and prednisone or dexamethasone, yield a complete remission rate of only about 5%, and median survival is approximately 36-48 months from the time of diagnosis. Recent advances using high dose chemotherapy followed by autologous bone marrow or peripheral blood mononuclear cell transplantation have increased the complete remission rate and remission duration. Nevertheless, overall survival has only been slightly prolonged, and no evidence for a cure has been obtained. Ultimately, all MM patients relapse, even under maintenance therapy with interferon-alpha (IFN-Į) alone or in combination with steroids.
Efficacy of the available drug treatment regimens for MM is limited by the low cell proliferation rate and development of drug resistance in up to 90% of patients.
Chromosomal translocations, oncogene mutations, dysregulated signaling pathways such as anti-apoptotic and survival pathways and bone marrow niche been implicated to contribute to drug resistance in MM (for review, see Abdi et al., Oncotarget 4:2186-2207, 2013). The bone marrow (BM) niche is implicated in proliferation, survival, differentiation, migration, and drug resistance of the malignant plasma cells (Manier et al., J Biomed Biotechnol 2012; published online 2012 October 3,
doi:_10.1155/_2012/_157496).
CD38, a type II transmembrane glycoprotein is an attractive target for antibody therapeutics for various heme malignancies, including multiple myeloma. Anti-CD38 antibodies are described, for example, in Intl. Pat. Publ. No. WO2008/037257, Intl. Pat. Publ. No. WO2008/047242 and Intl. Pat. Publ. No. WO2007/042309, and are being evaluated in clinical settings for their efficacy in multiple myeloma and other heme malignancies. SUMMARY OF THE INVENTION
The invention provides for a method of treating a subject having a CD38-positive hematological malignancy, comprising administering to the subject in need thereof an anti- CD38 antibody and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1A. Bone Marrow stromal cells (BMSCs) mediate protection against multiple myeloma (MM) cell killing by ADCC induced by anti-CD38 antibody daratumumab in MM cell lines. Luciferase transduced CD38+ UM9 MM cells were cultured in the presence or absence of healthy donor BMSCs (HD-BMSCs) for 16 hours prior to incubation with serial concentrations of daratumumab and HD-PBMCs at a PBMC:MM cell ratio of 30:1. MM cell viability was determined after 4 hours by bioluminescence imaging (BLI). Percent (%) ADCC was calculated relative to the cell viability without daratumumab. Error bars indicate the standard error of the mean (SEM) of triplicate measurements. The data are representative for 3 independent experiments. The differences between cultures with or without BMSCs were tested with an unpaired t test *= p<0.05. Figure 1B. Bone Marrow stromal cells (BMSCs) mediate protection against multiple myeloma (MM) cell killing by ADCC induced by anti-CD38 antibody daratumumab in MM cell lines. Luciferase transduced CD38+ RPMI8226 MM cells were cultured in the presence or absence of HD-BMSCs for 16 hours prior to incubation with serial concentrations of daratumumab and HD-PBMCs at a PBMC:MM cell ratio of 30:1. MM cell viability was determined after 4 hours by BLI. % ADCC was calculated relative to the cell viability without daratumumab. Error bars indicate the SEM of triplicate measurements. The data are representative for 3 independent experiments. The differences between cultures with or without BMSCs were tested with an unpaired t test *= p<0.05. Figure 2A. BMSCs mediate protection against MM cell killing by ADCC induced by anti-CD38 antibody daratumumab in primary MM patient samples. Full Bone marrow aspirates obtained from MM patient 1 was cultured in the presence (white bars) or absence (black bars) of autologous bone marrow stromal cells and then treated with daratumumab at indicated concentrations. The autologous cells present in aspirate were used as effector cells. Since BM-MNCs already contain NK cells as effector cells, no additional effector cells were added. The viability of CD138+ MM cells in the cultures was determined after 24 hours by flow cytometry. Error bars indicate the SEM of triplicate measurements. The differences between cultures with or without BMSCs were tested with an unpaired t test. *= p<0.05. Top panel: patient #1, Bottom panel; patient #2. BMSC: bone marrow stromal cell. ADCC: antibody-dependent cell cytotoxicity.
Figure 2B. BMSCs mediate protection against MM cell killing by ADCC induced by anti- CD38 antibody daratumumab in primary MM patient samples. Full Bone marrow aspirates obtained from MM patient 2 was cultured in the presence (white bars) or absence (black bars) of autologous bone marrow stromal cells and then treated with daratumumab at indicated concentrations. The autologous cells present in aspirate were used as effector cells. Since BM-MNCs already contain NK cells as effector cells, no additional effector cells were added. The viability of CD138+ MM cells in the cultures was determined after 24 hours by flow cytometry. Error bars indicate the SEM of triplicate measurements. The differences between cultures with or without BMSCs were tested with an unpaired t test. *= p<0.05. Top panel: patient #1, Bottom panel; patient #2. BMSC: bone marrow stromal cell. ADCC: antibody-dependent cell cytotoxicity.
Figure 3. YM155 does not induce NK cell lysis. HD-PBMCs and patient bone marrow mononuclear cells (BMMNCs) were incubated with the indicated concentrations of YM155 for 24 hours. The number of viable CD3- CD56+ NK cells was determined by flow cytometry and the percent lysis was calculated using the untreated samples as negative control.
Figure 4A. Daratumumab in combination with YM155 provide synergistic effect on MM cell killing by ADCC in the presence of stromal cells. Luciferase transduced RPMI8226 MM cells were cultured in presence or absence of HD-BMSCs. Daratumumab and YM155 were added at the indicated concentrations. HD-PBMCs were added in all wells at a PBMC:MM ratio of 40:1 as a source of NK cells to induce ADCC. RPMI8226 cell survival was determined after 4 hours by BLI. The % lysis was calculated relative to the survival of RPMI8226 cells that did not receive any treatment. In the case of the YM155 and daratumumab combination, the expected lysis values were deduced from
daratumumab and YM155 treatment alone, assuming that the cumulative effect would be additive, but not synergistic. The statistical differences between the expected and observed results were determined in a paired t test *** =P<0.005, *= P<0.05. DARA: daratumumab.
Figure 4B. Daratumumab in combination with YM155 provides synergistic effect on primary MM cell killing by ADCC in the presence of stromal cells. Full BM aspirates of the MM patient 1 were cultured in the presence or absence of autologous MM-BMSCs. Daratumumab and YM155 were added at the indicated concentrations. Since BM-MNCs contain sufficient NK cells (in both cases, approximately at a 30:1 NK: MM cell ratio), no additional effector cells were added. After 24 hours, the viable CD138+ MM cells were enumerated in each condition via flow cytometry. The % lysis was calculated relative to the survival of MM cells in BM-MNCs which were cultured at the same conditions but did not receive any treatment. The statistical differences between the expected and observed results were determined in a paired t test. *= P<0.05. Figure 4C. Daratumumab in combination with YM155 provides synergistic effect on primary MM cell killing by ADCC in the presence of stromal cells. Full BM aspirates of the MM patient 2 were cultured in the presence or absence of autologous MM-BMSCs. Daratumumab and YM155 were added at the indicated concentrations. Since BM-MNCs contain sufficient NK cells (in both cases, approximately at a 30:1 NK: MM cell ratio), no additional effector cells were added. After 24 hours, the viable CD138+ MM cells were enumerated in each condition via flow cytometry. The % lysis was calculated relative to the survival of MM cells in BM-MNCs which were cultured at the same conditions but did not receive any treatment. The statistical differences between the expected and observed results were determined in a paired t test. *= P<0.05. Figure 4D. Daratumumab in combination with YM155 provides synergistic effect on primary MM cell killing by ADCC in the presence of stromal cells. Bone marrow mononuclear cells (BM-MNCs) from four MM patients containing CD138+ MM cells (45%, 5.5% 10.2% 21.6% for patient 1-4, respectively) were cultured in the presence or absence of autologous MM-BMSCs. Daratumumab (1 ng/ml) and appropriate sub maximal concentrations of YM155 (125, 62, 75 and 50 ng/ml for patient 1-4, respectively) were added. Since BM-MNCs contained sufficient NK cells (7.9%, 7.9%, 10.3% and 9.5% respectively), no additional effector cells were added. After 24 hours, the viable CD138+ MM cells were enumerated in each condition via flow cytometry. The % lysis was calculated relative to the survival of MM cells in BM-MNCs which were cultured at the same conditions but did not receive any treatment. The statistical differences between the expected and observed results were determined in a paired t test. *= P<0.05. ns: not significant. DARA: daratumumab. Figure 5. Antitumor effect of daratumumab and YM155 combination therapy. Analysis of tumor load per treatment group in RAG2í/íȖcí/í mice implanted with UM9 cells.
Hybrid scaffolds coated with human MSCs and loaded with luciferase transduced MM cell line UM9 were implanted subcutaneously in the back of RAG2í/íȖcí/í mice (4 scaffolds per mice). Ten days after implantation, the growing tumors were visualized and quantified by BLI. Different groups of mice (n=4) were then either treated with vehicle control (control) or treated with daratumumab, YM155 or daratumumab plus YM155 as indicated. YM155 (or its vehicle, PBS) was delivered with subcutaneous infusion pumps at a rate of 1 mg/kg/d YM155 for 10 days. Each mouse, including those in the control group, received T cell depleted HD-PBMCs (5x106 cells) as a source of human NK cells to induce ADCC. Mice were monitored weekly by BLI. Results are expressed as the mean tumor load in each scaffold. The error bars represent the SEM. The statistical differences between mice treated with daratumumab and mice treated with daratumumab plus YM155 were calculated using the Mann-Whitney U-test.
*** P<0.001. DETAILED DESCRIPTION OF THE INVENTION
“CD38” refers to the human CD38 protein (synonyms: ADP-ribosyl cyclase 1, cADPr hydrolase 1, cyclic ADP-ribose hydrolase 1). Human CD38 has an amino acid sequence as shown in SEQ ID NO: 1. it is well known that CD38 is a single pass type II membrane protein with amino acid residues 1-21 representing the cytosolic domain, amino acid residues 22-42 representing the transmembrane domain, and residues 43-300 representing the extracellular domain of CD38.
The term“antibodies” as used herein is meant in a broad sense and includes immunoglobulin molecules including, monoclonal antibodies including murine, human, human-adapted, humanized and chimeric monoclonal antibodies, antibody fragments, bispecific or multispecific antibodies, dimeric, tetrameric or multimeric antibodies, and single chain antibodies.
Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub-classified as the isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda based on the amino acid sequences of
Figure imgf000007_0001
Figure imgf000007_0002
their constant domains.
The term“antibody fragments” refers to a portion of an immunoglobulin molecule that retains the heavy chain and/or the light chain antigen binding site, such as heavy chain complementarity determining regions (HCDR) 1, 2 and 3, light chain complementarity determining regions (LCDR) 1, 2 and 3, a heavy chain variable region (VH), or a light chain variable region (VL). Antibody fragments include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CHI domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a domain antibody (dAb) fragment (Ward et al., Nature 341:544- 546, 1989), which consists of a VH domain. VH and VL domains can be engineered and linked together via a synthetic linker to form various types of single chain antibody designs where the VH/VL domains pair intramolecularly, or
intermolecularly in those cases when the VH and VL domains are expressed by separate single chain antibody constructs, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in Intl. Pat. Publ. Nos. WO1998/44001, WO1988/01649, WO1994/13804, and WO1992/01047. These antibody fragments are obtained using well known techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are full length antibodies.
The phrase "isolated antibody" refers to an antibody or antibody fragment that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody specifically binding CD38 is substantially free of antibodies that specifically bind antigens other than human CD38). An isolated antibody that specifically binds CD38, however, can have cross-reactivity to other antigens, such as orthologs of human CD38, such as Macaca fascicularis (cynomolgus) CD38. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals. An antibody variable region consists of a“framework” region interrupted by three “antigen binding sites”. The antigen binding sites are defined using various terms: (i) Complementarity Determining Regions (CDRs), three in the VH (HCDR1, HCDR2, HCDR3), and three in the VL (LCDR1, LCDR2, LCDR3) are based on sequence variability (Wu and Kabat J Exp Med 132:211-50, 1970; Kabat et al Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991). (ii)“Hypervariable regions”,“HVR”, or“HV”, three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3) refer to the regions of an antibody variable domains which are hypervariable in structure as defined by Chothia and Lesk (Chothia and Lesk Mol Biol 196:901-17, 1987). Other terms include“IMGT-CDRs” (Lefranc et al., Dev Comparat Immunol 27:55-77, 2003) and“Specificity Determining Residue Usage” (SDRU) (Almagro Mol Recognit 17:132-43, 2004). The International ImMunoGeneTics (IMGT) database (http://www_imgt_org) provides a standardized numbering and definition of antigen-binding sites. The correspondence between CDRs, HVs and IMGT delineations is described in Lefranc et al., Dev Comparat Immunol 27:55-77, 2003. “Chothia residues” as used herein are the antibody VL and VH residues numbered according to Al-Lazikani (Al-Lazikani et al., J Mol Biol 273:927-48, 1997).
“Framework” or“framework sequences” are the remaining sequences of a variable region other than those defined to be antigen binding sites. Because the antigen binding sites can be defined by various terms as described above, the exact amino acid sequence of a framework depends on how the antigen-binding site was defined.
“Humanized antibody” refers to an antibody in which the antigen binding sites are derived from non-human species and the variable region frameworks are derived from human immunoglobulin sequences. Humanized antibodies may include substitutions in the framework regions so that the framework may not be an exact copy of expressed human immunoglobulin or germline gene sequences.
“Human antibody” refers to an antibody having heavy and light chain variable regions in which both the framework and the antigen binding sites are derived from sequences of human origin. If the antibody contains a constant region, the constant region also is derived from sequences of human origin.
A human antibody comprises heavy or light chain variable regions that are “derived from” sequences of human origin if the variable regions of the antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes. Such systems include human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice carrying human immunoglobulin loci as described herein.“Human antibody” may contain amino acid differences when compared to the human germline or rearranged immunoglobulin sequences due to for example naturally occurring somatic mutations or intentional introduction of substitutions in the framework or antigen binding sites. Typically, a “human antibody” is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical in amino acid sequence to an amino acid sequence encoded by a human germline or rearranged immunoglobulin gene. In some cases, a“human antibody” may contain consensus framework sequences derived from human framework sequence analyses, for example as described in Knappik et al., J Mol Biol 296:57-86, 2000), or synthetic HCDR3 incorporated into human immunoglobulin gene libraries displayed on phage, as described in, for example, Shi et al., J Mol Biol 397:385-96, 2010 and Intl. Pat. Publ. No.
WO2009/085462). Antibodies in which antigen binding sites are derived from a non- human species are not included in the definition of“human antibody”.
Isolated humanized antibodies may be synthetic. Human antibodies, while derived from human immunoglobulin sequences, may be generated using systems such as phage display incorporating synthetic CDRs and/or synthetic frameworks, or can be subjected to in vitro mutagenesis to improve antibody properties, resulting in antibodies that do not naturally exist within the human antibody germline repertoire in vivo.
“Recombinant antibody” includes all antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described further below), antibodies isolated from a host cell transformed to express the antibody, antibodies isolated from a recombinant, combinatorial antibody library, and antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences, or antibodies that are generated in vitro using Fab arm exchange.
"Monoclonal antibody" refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope, or in a case of a bispecific monoclonal antibody, a dual binding specificity to two distinct epitopes.“Monoclonal antibody” therefore refers to an antibody population with single amino acid composition in each heavy and each light chain, except for possible well known alterations such as removal of C-terminal lysine from the antibody heavy chain. Monoclonal antibodies may have heterogeneous glycosylation within the antibody population. Monoclonal antibody may be monospecific or multispecific, or monovalent, bivalent or multivalent. A bispecific antibody is included in the term monoclonal antibody.
"Epitope" refers to a portion of an antigen to which an antibody specifically binds. Epitopes usually consist of chemically active (such as polar, non-polar or hydrophobic) surface groupings of moieties such as amino acids or polysaccharide side chains and can have specific three-dimensional structural characteristics, as well as specific charge characteristics. An epitope can be composed of contiguous and/or discontiguous amino acids that form a conformational spatial unit. For a discontiguous epitope, amino acids from differing portions of the linear sequence of the antigen come in close proximity in 3- dimensional space through the folding of the protein molecule.
“Variant” refers to a polypeptide or a polynucleotide that differs from a reference polypeptide or a reference polynucleotide by one or more modifications for example, substitutions, insertions or deletions.
“In combination with” means that two or more therapeutics can be administered to a subject together in a mixture, concurrently as single agents or sequentially as single agents in any order.
“Treat” or“treatment” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development or spread of a tumor or tumor cells. Beneficial or desired clinical results include alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable and prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
“Therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic or combination of therapeutics that may decline or abate in association with resistance include, for example, improved well-being of the patient, reduction of a tumor burden, arrested or slowed growth of a tumor, and/or absence of metastasis of cancer cells to other locations in the body. “Synergy”,“synergism” or“synergistic” mean more than the expected additive effect of a combination.
“Inhibits growth” (e.g., referring to cells, such as tumor cells) refers to a measurable decrease in the cell growth in vitro or in vivo when contacted with a therapeutic or a combination or therapeutics or drugs when compared to the growth of the same cells grown in appropriate control conditions well known to the skilled in the art. Inhibition of growth of a cell in vitro or in vivo may be at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. Inhibition of cell growth can occur by a variety of mechanisms, for example by ADCC, apoptosis, necrosis, or by inhibition of cell proliferation.
“Subject” includes any human or nonhuman animal.“Nonhuman animal” includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows chickens, amphibians, reptiles, etc. The terms“subject” and“patient” are used interchangeably herein.
“Survivin” as used herein refers to the survivin protein having the amino acid sequence shown in SEQ ID NO: 22. Survivin is a member of the inhibitor of apoptosis (IAP) family. Survivin is a dual functional protein acting as an apoptosis inhibitor and cell cycle regulator. Overexpression of survivin is observed in human malignancies and positively correlates with poor prognosis, tumor recurrence, and therapeutic resistance (Liu et al., Cancer Biol. Ther., 7:1053-1060, 2008; Mita et al., Clin Cancer Res., 14:5000- 5005, 2008). SEQ ID NO: 22
MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLA QCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKN KIAKETNNKKKEFEETAEKVRRAIEQLAAMD “Survivin inhibitor” refers to a molecule that inhibits, antagonizes, reduces or suppresses survivin activity; e.g., a molecule that inhibits the anti-apoptotic activity of survivin in a cell. Survivin inhibitor may inhibit the anti-apoptotic activity of survivin by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. Survivin inhibitors may be a small molecule, peptide, a vaccine, a polynucleotide, DNA or RNA molecule.
The present invention is based, at least in part, on the finding that bone marrow stromal cells (BMSC) residing in the BM niche protect MM cells against antibody-induced ADCC at least in part by upregulating survivin, and that survivin inhibitors improve antibody-mediated ADCC of MM cells and abrogate ADCC resistance induced by BMSCs. BMSCs have been shown to protect MM cells from cytotoxic T-lymphocyte (CTL)-dependent lysis via cell adhesion-mediated immune resistance, and survivin has been found to be upregulated in the lysis-resistant MM cells (de Haart et al., Clin Cance Res 19:5591-5601, 2013).
The invention provides for a method of treating a subject having a CD38-positive hematological malignancy, comprising administering to the subject in need thereof an anti- CD38 antibody and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy..
The invention also provides for a method of inhibiting growth or proliferation of multiple myeloma cells in a subject, comprising administering an anti-CD38 antibody and a survivin inhibitor to the subject in need thereof for a time sufficient to inhibit growth or proliferation of multiple myeloma cells.
“CD38-positive hematological malignancy” refers to a hematological malignancy characterized by the presence of tumor cells expressing CD38, including leukemias, lymphomas and myeloma. Exemplary such CD38-positive hematological malignancies are precursor B-cell lymphoblastic leukemia/lymphoma and B-cell non-Hodgkin's lymphoma, acute promyelocytic leukemia, acute lymphoblastic leukemia and mature B- cell neoplasms, such as B-cell chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), B-cell acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL), including low-grade, intermediate- grade and high-grade FL, cutaneous follicle center lymphoma, marginal zone B-cell lymphoma (MALT type, nodal and splenic type), hairy cell leukemia, diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), plasmacytoma, multiple myeloma (MM), plasma cell leukemia, post-transplant
lymphoproliferative disorder, Waldenstrom's macroglobulinemia, plasma cell leukemias and anaplastic large-cell lymphoma (ALCL).
CD38 is expressed in a variety of malignant hematological diseases, including multiple myeloma, leukemias and lymphomas, such as B-cell chronic lymphocytic leukemia, T- and B-cell acute lymphocytic leukemia, Waldenstrom’s macroglobulinemia, primary systemic amyloidosis, mantle-cell lymphoma, pro-lymphocytic/myelocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, follicular lymphoma, Burkitt’s lymphoma, large granular lymphocytic (LGL) leukemia, NK-cell leukemia and plasma-cell leukemia. Expression of CD38 has been described on epithelial/endothelial cells of different origin, including glandular epithelium in prostate, islet cells in pancreas, ductal epithelium in glands, including parotid gland, bronchial epithelial cells, cells in testis and ovary and tumor epithelium in colorectal adenocarcinoma. Other diseases, where CD38 expression could be involved include, e.g., broncho-epithelial carcinomas of the lung, breast cancer (evolving from malignant proliferation of epithelial lining in ducts and lobules of the breast), pancreatic tumors, evolving from the E-cells (insulinomas), tumors evolving from epithelium in the gut (e.g. adenocarcinoma and squamous cell carcinoma), carcinoma in the prostate gland, and seminomas in testis and ovarian cancers. In the central nervous system, neuroblastomas express CD38.
In some embodiments, the CD38-positive hematological malignancy is multiple myeloma (MM), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
In some embodiments, the CD38-positive hematological malignancy is MM.
In some embodiments, the CD38-positive hematological malignancy is ALL.
In some embodiments, the CD38-positive hematological malignancy is NHL.
In some embodiments, the CD38-positive hematological malignancy is DLBCL. In some embodiments, the CD38-positive hematological malignancy is BL.
In some embodiments, the CD38-positive hematological malignancy is FL.
In some embodiments, the CD38-positive hematological malignancy is MCL. In some embodiments, the CD38-positive hematological malignancy is AML. In some embodiments, the CD38-positive hematological malignancy is CLL.
In some embodiments, the CD38-positive hematological malignancy is a plasma cell disease.
In some embodiments, the plasma cell disease is light chain amyloidosis (AL), multiple myeloma (MM) or Waldenstrom’s macroglobulinemia.
In some embodiments, the plasma cell disease is AL.
In some embodiments, the plasma cell disease is MM.
In some embodiments, the plasma cell disease is Waldenstrom’s
macroglobulinemia.
Examples of B-cell non-Hodgkin's lymphomas are lymphomatoid granulomatosis, primary effusion lymphoma, intravascular large B-cell lymphoma, mediastinal large B-cell lymphoma, heavy chain diseases (including Ȗ, ^, and a disease), lymphomas induced by therapy with immunosuppressive agents, such as cyclosporine-induced lymphoma, and methotrexate-induced lymphoma. In one embodiment, the disorder involving cells expressing CD38 is Hodgkin's lymphoma.
Other examples of disorders involving cells expressing CD38 include malignancies derived from T and NK cells including mature T cell and NK cell neoplasms including T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T-cell leukemia/lymphoma, extranodal NK/T cell lymphoma, nasal type, 78 enteropathy-type T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, blastic NK cell lymphoma, Mycosis Fungoides/Sezary Syndrome, primary cutaneous CD30 positive T-cell lymphoproliferative disorders (primary cutaneous anaplastic large cell lymphoma C- ALCL, lymphomatoid papulosis, borderline lesions), angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma unspecified, and anaplastic large cell lymphoma.
Examples of malignancies derived from myeloid cells include acute myeloid leukemia, including acute promyelocytic leukemia, and chronic myeloproliferative diseases, including chronic myeloid leukemia.
Any anti-CD38 antibody may be used in the methods of the invention. The variable regions of the anti-CD38 antibodies may be obtained from existing anti-CD38 antibodies and optionally cloned as full length antibodies using standard methods.
Exemplary antibody variable regions binding CD38 that may be used are described for example in Intl. Pat. Publ. Nos. WO05/103083, WO06/125640, WO07/042309, WO08/047242, WO12/092612, WO06/099875, and WO11/154453A1.
An exemplary anti-CD38 antibody that may be used is DARZALEXTM
(daratumumab). DARZALEXTM (daratumumab) comprises a heavy chain variable region (VH) and a light chain variable region (VL) amino acid sequences as shown in SEQ ID NO: 4 and 5, respectively, a heavy chain complementarity determining region (HCDR) 1, a HCDR2 and a HCDR3 amino acid sequences as shown in SEQ ID NOs: 6, 7 and 8, respectively, and a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 amino acid sequences as shown in SEQ ID NOs: 9, 10 and 11, respectively, and is of IgG1/N subtype. DARZALEXTM (daratumumab) heavy chain amino acid sequence is shown in SEQ ID NO: 12 and light chain amino acid sequence shown in SEQ ID NO: 13. SEQ ID NO: 1
MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGT TKRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLM KLGTQTVPCNKILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFN TSKINYQSCPDWRKDCSNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDK NSTFGSVEVHNLQPEKVQTLEAWVIHGGREDSRDLCQDPTIKELESIISKRNIQFSC KNIYRPDKFLQCVKNPEDSSCTSEI SEQ ID NO: 2
SKRNIQFSCKNIYR SEQ ID NO: 3
EKVQTLEAWVIHGG SEQ ID NO: 4
EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSA ISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDK ILWFGEPVFDYWGQGTLVTVSS SEQ ID NO: 5
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYD ASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQ GTKVEIK SEQ ID NO: 6
SFAMS SEQ ID NO: 7
AISGSGGGTYYADSVKG SEQ ID NO: 8
DKILWFGEPVFDY SEQ ID NO: 9
RASQSVSSYLA SEQ ID NO: 10
DASNRAT SEQ ID NO: 11
QQRSNWPPTF SEQ ID NO: 12
EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSG GGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVF DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK SEQ ID NO: 13
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRAT GIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Another exemplary anti-CD38 antibody that may be used is mAb003 comprising the VH and VL sequences of SEQ ID NOs: 14 and 15, respectively and described in U.S. Pat. No.7,829,693. SEQ ID NO: 14
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAFSWVRQAPGQGLEWMGRVIPF LGIANSAQKFQGRVTITADKSTSTAY MDLSSLRSEDTAVYYCARDDIAALGPFDYWGQGTLVTVSSAS SEQ ID NO: 15
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQS GVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYNSYPRTFGQGTKVEIK Another exemplary anti-CD38 antibody that may be used is mAb024 comprising the VH and VL sequences of SEQ ID NOs: 16 and 17, respectively and described in U.S. Pat. No.7,829,693. SEQ ID NO: 16
EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIYPH DSDARYSPSFQGQVTFSADKSISTAY LQWSSLKASDTAMYYCARHVGWGSRYWYFDLWGRGTLVTVSS SEQ ID NO: 17
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRAT GIPARFSGSGSGTDFTLTISSLEP EDFAVYYCQQRSNWPPTFGQGTKVEIK Another exemplary anti-CD38 antibody that may be used is MOR-202 (MOR- 03087) comprising the VH and VL sequences of SEQ ID NOs: 18 and 19, respectively and described in US. Pat. No.8,088,896. SEQ ID NO: 18
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGD PSNTYYADSVKGRFTISRDNSKNTLY LQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS SEQ ID NO: 19
DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPS GIPERFSGSNSGNTATLTISGTQAE DEADYYCQTYTGGASLVFGGGTKLTVLGQ Another exemplary anti-CD38 antibody that may be used is isatuximab, comprising the VH and VL sequences of SEQ ID NOs: 20 and 21, respectively, described in U.S. Pat. No.8,153,765. The VH and the VL of isatuximab may be expressed as IgG1/N. SEQ ID NO: 20
QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGT IYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGD YYGSNSLDYWGQGTSVTVSS SEQ ID NO: 21
DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYS ASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGG GTKLEIK Anti-CD38 antibodies used in the methods of the invention may also be selected de novo from for example a phage display library, where the phage is engineered to express human immunoglobulins or portions thereof such as Fabs, single chain antibodies (scFv), or unpaired or paired antibody variable regions (Knappik et al., J Mol Biol 296:57- 86, 2000; Krebs et al., J Immunol Meth 254:67-84, 2001; Vaughan et al., Nature Biotechnology 14:309-314, 1996; Sheets et al., PITAS (USA) 95:6157-6162, 1998;
Hoogenboom and Winter, J Mol Biol 227:381, 1991; Marks et al., J Mol Biol 222:581, 1991). CD38 binding variable domains may be isolated for example from phage display libraries expressing antibody heavy and light chain variable regions as fusion proteins with bacteriophage pIX coat protein as described in Shi et al (2010) J. Mol. Biol.397:385-96 and Intl. Pat. Publ. No. WO09/085462). The antibody libraries may be screened for binding to human CD38 extracellular domain and the obtained positive clones may be further characterized and the Fabs isolated from the clone lysates, and subsequently cloned as full length antibodies. Such phage display methods for isolating human antibodies are established in the art. See for example: US Pat. No.5,223,409; US Pat. No.5,403,484; and US Pat. No.5,571,698, US Pat. No.5,427,908, US Pat. No.5, 580,717, US Pat. No. 5,969,108, US Pat. No.6,172,197, US Pat. No.5,885,793; US Pat. No.6,521,404; US Pat. No.6,544,731; US Pat. No.6,555,313; US Pat. No.6,582,915 and US Pat. No.6,593,081.
The invention also provides for a method of treating a subject having a CD38- positive hematological malignancy, comprising administering to the subject in need thereof an anti-CD38 antibody that competes for binding to CD38 with an antibody comprising the VL of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy.
The invention also provides for a method of treating a subject having multiple myeloma, comprising administering to the subject in need thereof an anti-CD38 antibody that competes for binding to CD38 with an antibody comprising the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 and a survivin inhibitor for a time sufficient to treat multiple myeloma.
The invention also provides for a method of treating a subject having a CD38- positive hematological malignancy, comprising administering to the subject in need thereof an anti-CD38 antibody that binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy.
The invention also provides for a method of treating a subject having multiple myeloma, comprising administering to the subject in need thereof an anti-CD38 antibody that binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region
EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1).and a survivin inhibitor for a time sufficient to treat multiple myeloma.
In some embodiments, the anti-CD38 antibody comprises the HCDR1, the HCDR2 and hte HCDR2 of SEQ ID NOs: 6, 7 and 8, respectively.
In some embodiments, the anti-CD38 antibody comprises the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 9, 10 and 11, respectively.
In some embodiments, the anti-CD38 antibody comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively.
In some embodiments, the anti-CD38 antibody comprises the VL comprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 4 and the VL omprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 5.
In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5.
In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 15.
In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO: 16 and the VL of SEQ ID NO: 17
In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO: 18 and the VL of SEQ ID NO: 19.
In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO: 20 and the VL of SEQ ID NO: 21. Antibodies may be evaluated for their competition with a reference antibody, for example DARZALEXTM (daratumumab having the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5 for binding to CD38 using well known in vitro methods. In an exemplary method, CHO cells recombinantly expressing CD38 may be incubated with unlabeled reference antibody for 15 min at 4qC, followed by incubation with an excess of fluorescently labeled test antibody for 45 min at 4qC. After washing in PBS/BSA, fluorescence may be measured by flow cytometry using standard methods. In another exemplary method, extracellular portion of human CD38 may be coated on the surface of an ELISA plate. Excess of unlabelled reference antibody may be added for about 15 minutes and subsequently biotinylated test antibodies may be added. After washes in PBS/Tween, binding of the test biotinylated antibody may be detected using horseradish peroxidase (HRP)-conjugated streptavidin and the signal detected using standard methods. It is readily apparent that in the competition assays, the reference antibody may be labeled and the test antibody unlabeled. The test antibody competes with the reference antibody when the reference antibody inhibits binding of the test antibody, or the test antibody inhibits binding of the reference antibody by at least 80%, 85%, 90% , 95% or 100%. The epitope of the test antibody may further be defined for example by peptide mapping or hydrogen/deuterium protection assays using known methods, or by crystal structure determination.
An anti-CD38 antibody binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) when the antibody binds at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 residues within SEQ ID NO: 2 and SEQ ID NO: 3. In some embodiments, the anti-CD38 antibody binds at least one amino acid in the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and at least one amino acid in the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1). In some embodiments, the anti-CD38 antibody binds at least two amino acids in the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and at least two amino acids in the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1). In some embodiments, the anti-CD38 antibody binds at least three amino acids in the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and at least three amino acids in the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1). An exemplary antibody that binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) is DARZALEXTM (daratumumab).
Antibodies binding to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1) may be generated for example by immunizing mice with peptides having the amino acid sequences shown in SEQ ID NOs: 2 and 3 using standard methods and as described herein, and characterizing the obtained antibodies for binding to the peptides using for example ELISA or mutagenesis studies.
The Fc portion of the antibody may mediate antibody effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) or complement dependent cytotoxicity (CDC), as described in more detail below. Such functions may be mediated by binding of an Fc effector domain(s) to an Fc receptor on an immune cell with phagocytic or lytic activity or by binding of an Fc effector domain(s) to components of the complement system. Typically, the effect(s) mediated by the Fc-binding cells or complement components result in inhibition and/or depletion of target cells, e.g., CD38-expressing cells. Human IgG isotypes IgG1, IgG2, IgG3 and IgG4 exhibit differential capacity for effector functions. ADCC may be mediated by IgG1 and IgG3, ADCP may be mediated by IgG1, IgG2, IgG3 and IgG4, and CDC may be mediated by IgG1 and IgG3.
In some embodiments, the anti-CD38 antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the anti-CD38 antibody is of IgG1 isotype.
In some embodiments, the anti-CD38 antibody is of IgG2 isotype.
In some embodiments, the anti-CD38 antibody is of IgG3 isotype.
In some embodiments, the anti-CD38 antibody is of IgG4 isotype.
In some embodiments, the anti-CD38 antibody induces killing of CD38- expressing cells by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or apoptosis.
In some embodiments, the anti-CD38 antibody induces killing of CD38- expressing cells by ADCC.
In some embodiments, the anti-CD38 antibody induces killing of CD38- expressing cells by ADCP.
In some embodimentsthe anti-CD38 antibody induces killing of CD38-expressing cells by CDC. In some embodiments, the anti-CD38 antibody induces killing of CD38- expressing cells by apoptosis.
"Antibody-dependent cellular cytotoxicity," "antibody-dependent cell-mediated cytotoxicity" or“ADCC" is a mechanism for inducing cell death that depends upon the interaction of antibody-coated target cells with effector cells possessing lytic activity, such as natural killer cells, monocytes, macrophages and neutrophils via Fc gamma receptors (FcJR) expressed on effector cells. For example, NK cells express FcJRIIIa, whereas monocytes express FcJRI, FcJRII and FcJRIIIa. Death of the antibody-coated target cell, such as CD38-expressing MM cell, occurs as a result of effector cell activity through the secretion of membrane pore-forming proteins and proteases. To assess ADCC activity of an anti-CD38 antibody, the antibody may be added to CD38-expressing cells in combination with immune effector cells, which may be activated by the antigen antibody complexes resulting in cytolysis of the target cell. Cytolysis may be detected by the release of label (e.g., radioactive substrates, fluorescent dyes or natural intracellular proteins) from the lysed cells. Exemplary effector cells for such assays include peripheral blood mononuclear cells (PBMC) and NK cells. Multiple myeloma cell lines or primary MM cells that express CD38 may be used as target cells. In an exemplary assay, MM cell lines engineered to express luciferase are incubated with anti-CD38 antibodies. Freshly isolated PBMC effector cells are added at target:effector cell ratio of 40:1.4 hours after addition of PBMC, luciferin is added and the resulting bioluminescent signal emitted from surviving MM cells determined within 20 minutes using a luminometer (SpectraMax, Molecular Devices), and the percentage ADCC of MM cells can calculated using the formula: % ADCC = 1 - (mean bioluminescent signal in the absence of PBMCs / mean bioluminescent signal in the presence of PBMCs) x100%. Anti-CD38 antibody“induces ADCC in vitro” when % ADCC in an in vitro assay such as one described above is at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 80%, 90% or 100% “Complement-dependent cytotoxicity”, or”CDC”, refers to a mechanism for inducing cell death in which an Fc effector domain of a target-bound antibody binds and activates complement component C1q which in turn activates the complement cascade leading to target cell death. Activation of complement may also result in deposition of complement components on the target cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on leukocytes. In an exemplary assay, primary BM- MNC cells isolated from a patient with a B-cell malignancy may be treated with an anti- CD38 antibody and complement derived from 10% pooled human serum for 1 hour at a concentration of 0.3-10 μg/ml, and the survival of primary CD138+ MM cells may be determined by flow cytometry using techniques described in van der Veer et al., Haematologica 96:284-290, 2011; van der Veer et al., Blood Cancer J 1(10):e41, 2011. The percentage of MM cell lysis may be determined relative to an isotype control as described herein. Anti-CD38 antibodies used in the methods of the invention may induce CDC by about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%
"Antibody-dependent cellular phagocytosis" ("ADCP") refers to a mechanism of elimination of antibody-coated target cells by internalization by phagocytic cells, such as macrophages or dendritic cells. ADCP may be evaluated by using monocyte-derived macrophages as effector cells and Daudi cells (ATCC® CCL-213™) or B cell leukemia or lymphoma tumor cells expressing CD38 as target cells engineered to express GFP or other labeled molecule. Effector:target cell ratio may be, for example, 4:1. Effector cells may be incubated with target cells for 4 hours with or without anti-CD38 antibody. After incubation, cells may be detached using accutase. Macrophages may be identified with anti-CD11b and anti-CD14 antibodies coupled to a fluorescent label, and percent phagocytosis may be determined based on % GFP fluorescent in the CD11+CD14+ macrophages using standard methods. Anti-CD38 antibodies used in the methods of the invention may induce ADCP by about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% .
ADCC elicited by anti-CD38 antibodies may be enhanced by certain substitutions in the antibody Fc. Exemplary substitutions are for example substitutions at amino acid positions 256, 290, 298, 312, 356, 330, 333, 334, 360, 378 or 430 (residue numbering according to the EU index) as described in U.S. Pat. No.6,737,056.
In some embodiments, the anti-CD38 antibodies comprise an amino acid substitution in the antibody Fc.
In some embodiments, the anti-CD38 antibodies comprise a substitution in the antibody Fc at amino acid positions 256, 290, 298, 312, 356, 330, 333, 334, 360, 378 or 430 (residue numbering according to the EU index).
ADCC elicted by anti-CD38 antibodies can also be enhanced by engineering the antibody oligosaccharide component. Human IgG1 or IgG3 are N-glycosylated at Asn297 with the majority of the glycans in the biantennary G0, G0F, G1, G1F, G2 or G2F forms. Antibodies produced by non-engineered CHO cells typically have a glycan fucose content of about at least 85%. The removal of the core fucose from the biantennary complex-type oligosaccharides attached to the Fc regions enhances the ADCC of antibodies via improved FcȖRIIIa binding without altering antigen binding or CDC activity. Such modified antibodies can be achieved using different methods reported to lead to the successful expression of relatively high defucosylated antibodies bearing the biantennary complex-type of Fc oligosaccharides such as control of culture osmolality (Konno et al., Cytotechnology 64(:249-65, 2012), application of a variant CHO line Lec13 as the host cell line (Shields et al., J Biol Chem 277:26733-26740, 2002), application of a variant CHO line EB66 as the host cell line (Olivier et al., MAbs ;2(4), 2010; Epub ahead of print; PMID:20562582), application of a rat hybridoma cell line YB2/0 as the host cell line (Shinkawa et al., J Biol Chem 278:3466-3473, 2003), introduction of small interfering RNA specifically against the D 1,6-fucosyltrasferase ( FUT8) gene (Mori et al., Biotechnol Bioeng88:901-908, 2004), or coexpression of ȕ-1,4-N-acetylglucosaminyltransferase III and Golgi Į-mannosidase II or a potent alpha-mannosidase I inhibitor, kifunensine (Ferrara et al., J Biol Chem281:5032-5036, 2006, Ferrara et al., Biotechnol Bioeng 93:851-861, 2006; Xhou et al., Biotechnol Bioeng 99:652-65, 2008).
In some embodiments, the anti-CD38 antibody has a biantennary glycan structure with fucose content between about 0% to about 15%, for example 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%.
In some embodiments, the anti-CD38 antibody has a biantennary glycan structure with fucose content of about 50%, 40%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%
Substitutions in the Fc and reduced fucose content may enhance the ADCC activity of the anti-CD38 antibody.
“Fucose content” means the amount of the fucose monosaccharide within the sugar chain at Asn297. The relative amount of fucose is the percentage of fucose- containing structures related to all glycostructures. These may be characterized and quantified by multiple methods, for example: 1) using MALDI-TOF of N-glycosidase F treated sample (e.g. complex, hybrid and oligo- and high-mannose structures) as described in Int Pat. Publ. No. WO2008/0775462); 2) by enzymatic release of the Asn297 glycans with subsequent derivatization and detection/ quantitation by HPLC (UPLC) with fluorescence detection and/or HPLC-MS (UPLC-MS); 3) intact protein analysis of the native or reduced mAb, with or without treatment of the Asn297 glycans with Endo S or other enzyme that cleaves between the first and the second GlcNAc monosaccharides, leaving the fucose attached to the first GlcNAc; 4) digestion of the antibody to constituent peptides by enzymatic digestion (e.g., trypsin or endopeptidase Lys-C), and subsequent separation, detection and quantitation by HPLC-MS (UPLC-MS); 5) Separation of the antibody oligosaccharides from the antibody protein by specific enzymatic
deglycosylation with PNGase F at Asn 297. The oligosaccharides thus released can be labeled with a fluorophore, separated and identified by various complementary techniques which allow: fine characterization of the glycan structures by matrix-assisted laser desorption ionization (MALDI) mass spectrometry by comparison of the experimental masses with the theoretical masses, determination of the degree of sialylation by ion exchange HPLC (GlycoSep C), separation and quantification of the oligosacharride forms according to hydrophilicity criteria by normal-phase HPLC (GlycoSep N), and separation and quantification of the oligosaccharides by high performance capillary electrophoresis- laser induced fluorescence (HPCE-LIF).
“Low fucose” or“low fucose content” as used in the application refers to antibodies with fucose content of about 0% to about15%.
“Normal fucose” or‘normal fucose content” as used herein refers to antibodies with fucose content of about over 50%, typically about over 80% or over 85%.
Antibodies that are substantially identical to the antibody comprising the heavy chain of SEQ ID NO: 12 and the light chain of SEQ ID NO: 13 may be used in the methods of the invention. The term“substantially identical” as used herein means that the two antibody heavy chain or light chain amino acid sequences being compared are identical or have“insubstantial differences”. Insubstantial differences are substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in an antibody heavy chain or light chain that do not adversely affect antibody properties. Percent identity can be determined for example by pairwise alignment using the default settings of the AlignX module of Vector NTI v.9.0.0 (Invitrogen, Carlsbad, CA). The protein sequences of the present invention can be used as a query sequence to perform a search against public or patent databases to, for example, identify related sequences. Exemplary programs used to perform such searches are the XBLAST or BLASTP programs
(http_//www_ncbi_nlm/nih_gov), or the GenomeQuestTM (GenomeQuest, Westborough, MA) suite using the default settings. Exemplary substitutions that can be made to the anti- CD38 antibodies used in the methods of the invention are for example conservative substitutions with an amino acid having similar charge, hydrophobic, or stereochemical characteristics. Conservative substitutions may also be made to improve antibody properties, for example stability or affinity, or to improve antibody effector functions. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid substitutions may be made, for example, to the heavy or the light chain of the anti-CD38 antibody. Furthermore, any native residue in the heavy or light chain may also be substituted with alanine, as has been previously described for alanine scanning mutagenesis (MacLennan et al., Acta Physiol Scand Suppl 643:55-67, 1998; Sasaki et al., Adv Biophys 35:1-24, 1998). Desired amino acid substitutions may be determined by those skilled in the art at the time such substitutions are desired. Amino acid substitutions may be done for example by PCR mutagenesis (U.S. Pat. No.4,683,195). Libraries of variants may be generated using well- known methods, for example using random (NNK) or non-random codons, for example DVK codons, which encode 11 amino acids (Ala, Cys, Asp, Glu, Gly, Lys, Asn, Arg, Ser, Tyr, Trp) and screening the libraries for variants with desired properties. The generated variants may be tested for their binding to CD38 and their ability to induce ADCC using methods described herein.
“Conservative modifications” refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequences. Conservative modifications include amino acid substitutions, additions and deletions. Conservative substitutions are those in which the amino acid is replaced with an amino acid residue having a similar side chain. The families of amino acid residues having similar side chains are well defined and include amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), basic side chains (e.g., lysine, arginine, histidine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), uncharged polar side chains (e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine, tryptophan), aromatic side chains (e.g., phenylalanine, tryptophan, histidine, tyrosine), aliphatic side chains (e.g., glycine, alanine, valine, leucine, isoleucine, serine, threonine), amide (e.g., asparagine, glutamine), beta- branched side chains (e.g., threonine, valine, isoleucine) and sulfur-containing side chains (cysteine, methionine). Furthermore, any native residue in the polypeptide may also be substituted with alanine, as has been previously described for alanine scanning mutagenesis (MacLennan et al., (1988) Acta Physiol Scand Suppl 643:55-67; Sasaki et al., (1988) Adv Biophys 35:1-24). Amino acid substitutions to the antibodies of the invention may be made by known methods for example by PCR mutagenesis (US Patent No.
4,683,195). Alternatively, libraries of variants may be generated for example using random (NNK) or non-random codons, for example DVK codons, which encode 11 amino acids (Ala, Cys, Asp, Glu, Gly, Lys, Asn, Arg, Ser, Tyr, Trp). The resulting antibody variants may be tested for their characteristics using assays described herein.
In some embodiments, the anti-CD38 antibody may bind human CD38 with a range of affinities (KD). In one embodiment, the anti-CD38 antibody binds to CD38 with a KD equal to or less than about 1x10-8 M, for example 5x10-9 M, 1x10-9 M, 5x10-10 M, 1x10-10 M, 5x10-11 M, 1x10-11 M, 5x10-12 M, 1x10-12 M, 5x10-13 M, 1x10-13 M, 5x10-14 M, 1x10-14 M or 5x10-15M, or any range or value therein, as determined by surface plasmon resonance or the Kinexa method, as practiced by those of skill in the art. An exemplary affinity is equal to or less than 1x10-8 M. Another exemplary affinity is equal to or less than 1x10-9 M.
KinExA instrumentation, ELISA or competitive binding assays known to those skilled in the art. The measured affinity of a particular antibody/ CD38 interaction may vary if measured under different conditions (e.g., osmolarity, pH). Thus, measurements of affinity and other binding parameters (e.g., K D , K on , K off ) are typically made with standardized conditions and a standardized buffer, such as the buffer described herein. Skilled in the art will appreciate that the internal error for affinity measurements for example using Biacore 3000 or ProteOn (measured as standard deviation, SD) may typically be within 5-33% for measurements within the typical limits of detection.
Therefore the term“about” in the context of KD reflects the typical standard deviation in the assay. For example, the typical SD for a KD of 1x10-9 M is up to +0.33x10-9 M.
In some embodiments, the anti-CD38 antibody is a bispecific antibody. The VL and/or the VH regions of existing anti-CD38 antibodies or the VL and VH regions identified de novo as described herein may be engineered into bispecific full length antibodies. Such bispecific antibodies may be made by modulating the CH3 interactions in antibody Fc to form bispecific antibodies using technologies such as those described in U.S. Pat. No.7,695,936; Int. Pat. Publ. No. WO04/111233; U.S. Pat. Publ. No.
US2010/0015133; U.S. Pat. Publ. No. US2007/0287170; Int. Pat. Publ. No.
WO2008/119353; U.S. Pat. Publ. No. US2009/0182127; U.S. Pat. Publ. No.
US2010/0286374; U.S. Pat. Publ. No. US2011/0123532; Int. Pat. Publ. No.
WO2011/131746; Int. Pat. Publ. No. WO2011/143545; or U.S. Pat. Publ. No.
US2012/0149876.
For example, bispecific antibodies of the invention may be generated in vitro in a cell-free environment by introducing asymmetrical mutations in the CH3 regions of two monospecific homodimeric antibodies and forming the bispecific heterodimeric antibody from two parent monospecific homodimeric antibodies in reducing conditions to allow disulfide bond isomerization according to methods described in Intl.Pat. Publ. No.
WO2011/131746. In the methods, the first monospecific bivalent antibody (e.g., anti- CD38 antibody) and the second monospecific bivalent antibody are engineered to have certain substitutions at the CH3 domain that promote heterodimer stability; the antibodies are incubated together under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide bond isomerization; thereby generating the bispecific antibody by Fab arm exchange. The incubation conditions may optimally be restored to non-reducing. Exemplary reducing agents that may be used are 2- mercaptoethylamine (2- MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2- carboxyethyl)phosphine (TCEP), L-cysteine and beta-mercaptoethanol, preferably a reducing agent selected from the group consisting of: 2- mercaptoethylamine, dithiothreitol and tris(2-carboxyethyl)phosphine. For example, incubation for at least 90 min at a temperature of at least 20°C in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM dithiothreitol at a pH of from 5-8, for example at pH of 7.0 or at pH of 7.4 may be used.
Exemplary CH3 mutations that may be used in a first heavy chain and in a second heavy chain of the bispecific antibody are K409R and/or F405L.
Additional bispecific structures into which the VL and/or the VH regions of the antibodies of the invention may be incorporated are for example Dual Variable Domain Immunoglobulins (DVD) (Int. Pat. Publ. No. WO2009/134776), or structures that include various dimerization domains to connect the two antibody arms with different specificity, such as leucine zipper or collagen dimerization domains (Int. Pat. Publ. No.
WO2012/022811, U.S. Pat. No.5,932,448; U.S. Pat. No.6,833,441). DVDs are full length antibodies comprising the heavy chain having a structure VH1-linker-VH2-CH and the light chain having the structure VL1-linker-VL2-CL; linker being optional.
In some embodiments, the anti-CD38 antibody is conjugated to a toxin.
Conjugation methods and suitable toxins are well known.
In some embodiments, the subject having MM is homozygous for phenylalanine at position 158 of CD16 (FcJRIIIa-158F/F genotype) or heterozygous for valine and pheynylalanine at position 158 of CD16 (FcJRIIIa-158F/V genotype). CD16 is also known as the Fc gamma receptor IIIa (FcJRIIIa) or the low affinity immunoglobulin gamma Fc region receptor III-A isoform. Valine/phenylalanine (V/F) polymorphism at FcJRIIIa protein residue position 158 has been shown to affect FcJRIIIa affinity to human IgG. Receptor with FcJRIIIa-158F/F or FcJRIIIa-158F/V polymorphisms demonstrates reduced Fc engagement and therefore reduced ADCC when compared to the FcJRIIIa- 158V/V. The lack of or low amount of fucose on human N-linked oligosaccharides improves the ability of the antibodies to induce ADCC due to improved binding of the antibodies to human FcJRIIIa (CD16) (Shields et al., J Biol Chem 277:26733-40, 2002). Patients can be analyzed for their FcJRIIIa polymorphism using routine methods. In some embodiments, the survivin inhibitor is a small molecule.
In some embodiments, the survivin inhibitor is a polynucleotide.
Survivin inhibitors may inhibit survivin-induced apoptosis by any mechanism, such as inhibiting survivin gene transcription or protein expression, inhibiting survivin protein dimerization, enhancing destabilization or inducing its degradation, etc.
An exemplary survivin small molecule inhibitor is YM155. YM155 binds to the survivin promoter and inhibits its transcription. Other exemplary survivin small molecule inhibitors are, for example, nordihydroguaiaretic acid derivatives as described in U.S. Pat. No.6,608,108, and molecules described in U.S. Pat. Publ. No. US2012/0122910. Other survivin polynucleotide inhibitors are described, for example, in U.S. Pat. No.6,838,283, Intl. Pat. Publ Nos. WO01/057059, WO09/114476 and WO09/044793. Polynucleotide inhibitors include microRNAs (miRNAs), small intereference RNAs (siRNAs), allele specific oligos (ASOs) and other polynucleotide inhibitors know in the art. Administration/ Pharmaceutical Compositions
In the methods of the invention, the anti-CD38 antibodies may be provided in suitable pharmaceutical compositions comprising the anti-CD38 antibody and a pharmaceutically acceptable carrier. The carrier may be diluent, adjuvant, excipient, or vehicle with which the anti-CD38 antibody is administered. Such vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. For example, 0.4% saline and 0.3% glycine can be used. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, thickening, lubricating and coloring agents, etc. The concentration of the molecules or antibodies of the invention in such pharmaceutical formulation may vary widely, i.e., from less than about 0.5%, usually to at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the particular mode of administration selected. Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in e.g. Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D.B. ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing pp 691-1092, See especially pp.958-989. The mode of administration of the anti-CD38 antibody in the methods of the invention may be any suitable route such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, pulmonary, transmucosal (oral, intranasal, intravaginal, rectal) or other means appreciated by the skilled artisan, as well known in the art.
The anti-CD38 antibody in the methods of the invention may be may administered to a patient by any suitable route, for example parentally by intravenous (IV) infusion or bolus injection, intramuscularly or subcutaneously or intraperitoneally. IV infusion can be given over for example 15, 30, 60, 90, 120, 180, or 240 minutes, or from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours.
The dose given to a patient having CD38-positive hematological malignancy is sufficient to alleviate or at least partially arrest the disease being treated (“therapeutically effective amount”) and may be sometimes 0.005 mg to about 100 mg/kg, e.g. about 0.05 mg to about 30 mg/kg or about 5 mg to about 25 mg/kg, or about 4 mg/kg, about 8 mg/kg, about 16 mg/kg or about 24 mg/kg , or for example about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg/kg, but may even higher, for example about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90 or 100 mg/kg.
A fixed unit dose may also be given, for example, 50, 100, 200, 500 or 1000 mg, or the dose may be based on the patient's surface area, e.g., 500, 400, 300, 250, 200, or 100 mg/m2. Usually between 1 and 8 doses, (e.g., 1, 2, 3, 4, 5, 6, 7 or 8) may be administered to treat MM, but 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more doses may be given.
The administration of the anti-CD38 antibody in the methods of the invention may be repeated after one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months or longer. Repeated courses of treatment are also possible, as is chronic administration. The repeated administration may be at the same dose or at a different dose. For example, the anti-CD38 antibody in the methods of the invention may be administered at 8 mg/ kg or at 16 mg/kg at weekly interval for 8 weeks, followed by administration at 8 mg/ kg or at 16 mg/kg every two weeks for an additional 16 weeks, followed by administration at 8 mg/ kg or at 16 mg/kg every four weeks by intravenous infusion.
The anti-CD38 antibodies may be administered in the methods of the invention by maintenance therapy, such as, e.g.,. once a week for a period of 6 months or more.
For example, anti-CD38 antibodies in the methods of the invention may be provided as a daily dosage in an amount of about 0.1-100 mg/kg, such as 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one of day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively, at least one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 after initiation of treatment, or any combination thereof, using single or divided doses of every 24, 12, 8, 6, 4, or 2 hours, or any combination thereof.
Anti-CD38 antibodies in the methods of the invention may also be administered prophylactically in order to reduce the risk of developing cancer, delay the onset of the occurrence of an event in cancer progression, and/or reduce the risk of recurrence when a cancer is in remission. This may be especially useful in patients wherein it is difficult to locate a tumor that is known to be present due to other biological factors.
The anti-CD38 antibody in the methods of the invention may be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional protein preparations and well known lyophilization and reconstitution techniques can be employed.
In the methods of the invention, the anti-CD38 antibody is administered in combination with a survivin inhibitor.
In the methods of the invention, the anti-CD38 antibody is administered in combination with a survivin inhibitor YM155.
YM155 used in the methods of the invention is readily available according to the processes of production as disclosed in International Publication Intl. Pat. Publ. Nos. WO01/60803 and WO2004/092160.
YM155 may be administered orally or parenterally, or intravenously. In this connection, the injection preparation for intravenous administration includes those containing sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The aqueous solvent includes, for example, distilled water for injection and physiological saline. The non-aqueous solvent includes, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80, and the like. Such compositions may contain further tonicity adjusting agents, antiseptics, moistening agents, emulsifying agents, dispersing agents, stabilizers, and solubilizing agents. These may be sterilized, for example, by filtration through a bacterial filter, blending of sterilizers or irradiation. Alternatively, it is possible to prepare a germ-free solid composition and dissolve or suspend it in sterile water or a sterile solvent for injection immediately before use. In intravenous administration, YM155 may be administered, for example, at 0.1- 20 mg/m2/day, such as at 1-10 mg/m2/day, once a day or divided in plural doses, or continuously by infusion (continuous instillation). YM155 may be infused at 3-10 mg/m2/day continuously for a period of 4 days to 20 days, for example 4 days to 14 days, or 5 days, 7 days, 10 days or 14 days, and or for 7 days. When the administration is further continued, a medication cycle may be employed comprising a term of drug holidays of 1 day to 2 months, 7 days to 21 days, or 14 days, after termination of the above term of medication. Alternatively, YM155 may be administered continuously by infusion at a dose of 3-8 mg/m2/day for 7 days, followed by drug holidays of 14 days; this cycle as one cycle is repeated depending on the conditions. The frequency of administration, dosage, time of infusion, medication cycle, and the like, may be determined properly according to individual cases considering the kind of anticancer agent, state of the patients, age, gender, etc.
In the methods of the invention, the combination of the anti-CD38 antibody and survivin inhibitor may be administered over any convenient timeframe. For example, the anti-CD38 antibody and survivin inhibitor may be administered to a patient on the same day. However, the anti-CD38 antibody and survivin may also be administered on alternating days or alternating weeks or months, and so on. In some methods, the anti- CD38 antibody and survivin inhibitor may be administered with sufficient proximity in time that they are simultaneously present (e.g., in the serum) at detectable levels in the patient being treated. In some methods, an entire course of treatment with the anti-CD38 antibody consisting of a number of doses over a time period is followed or preceded by a course of treatment with survivin inhibitor, consisting of a number of doses. A recovery period of 1, 2 or several days or weeks may be used between administration of the anti- CD38 antibody and survivin inhibitor.
Anti-CD38 antibody in combination with survivin inhibitor may be administered together with any form of radiation therapy including external beam radiation, intensity modulated radiation therapy (IMRT) and any form of radiosurgery including Gamma Knife, Cyberknife, Linac, and interstitial radiation (e.g., implanted radioactive seeds, GliaSite balloon), and/or with surgery. Subcutaneous administration of pharmaceutical compositions comprising an antibody that specifically binds CD38 and a hyaluronidase
The anti-CD38 antibody may be administered as a pharmaceutical composition comprising the anti-CD38 antibody and a hyaluronidase subcutaneously.
The concentration of the anti-CD38 antibody in the pharmaceutical composition administered subcutaneously may be about 20 mg/ml.
The pharmaceutical composition administered subcutaneously may comprise between about 1,200 mg– 1,800 mg of the anti-CD38 antibody.
The pharmaceutical composition administered subcutaneously may comprise about 1,200 mg of the anti-CD38 antibody.
The pharmaceutical composition administered subcutaneously may comprise about 1,600 mg of the anti-CD38 antibody.
The pharmaceutical composition administered subcutaneously may comprise about 1,800 mg of the anti-CD38 antibody.
The pharmaceutical composition administered subcutaneously may comprise between about 30,000 U– 45,000 U of the hyaluronidase.
The pharmaceutical composition administered subcutaneously may comprise about 1,200 mg of the anti-CD38 antibody and about 30,000 U of the hyaluronidase.
The pharmaceutical composition administered subcutaneously may comprise about 1,800 mg of the anti-CD38 antibody and about 45,000 U of the hyaluronidase.
The pharmaceutical composition administered subcutaneously may comprise about 1,600 mg of the anti-CD38 antibody and about 30,000 U of the hyaluronidase.
The pharmaceutical composition administered subcutaneously may comprise about 1,600 mg of the anti-CD38 antibody and about 45,000 U of the hyaluronidase.
The pharmaceutical composition administered subcutaneously may comprise the hyaluronidase rHuPH20 having the amino acid sequence of SEQ ID NO: 23.
rHuPH20 is a recombinant hyaluronidase (HYLENEX® recombinant) and is described in Int. Pat. Publ. No. WO2004/078140.
Hyaluronidase is an enzyme that degrades hyaluronic acid (EC 3.2.1.35) and lowers the viscosity of hyaluronan in the extracellular matrix, thereby increasing tissue permeability. SEQ ID NO: 23
MGVLKFKHIFFRSFVKSSGVSQIVFTFLLIPCCLTLNFRAPPVIPNVPFLWAWNAPS EFCLGKFDEPLDMSLFSFIGSPRINATGQGVTIFYVDRLGYYPYIDSITGVTVNGGIP QKISLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWARNWKPKDVYKNRS IELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHLWGYYLFPD CYNHHYKKPGYNGSCFNVEIKRNDDLSWLWNESTALYPSIYLNTQQSPVAATLY VRNRVREAIRVSKIPDAKSPLPVFAYTRIVFTDQVLKFLSQDELVYTFGETVALGA SGIVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCQEQGVCIR KNWNSSDYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCK EKADVKDTDAVDVCIADGVCIDAFLKPPMETEEPQIFYNASPSTLSATMFIVSILFLI ISSVASL The administration of the pharmaceutical composition comprising the anti-CD38 antibody and the hyaluronidase may be repeated after one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months or longer. Repeated courses of treatment are also possible, as is chronic administration. The repeated administration may be at the same dose or at a different dose. For example, the pharmaceutical composition comprising the anti-CD38 antibody and the hyaluronidase may be administered once weekly for eight weeks, followed by once in two weeks for 16 weeks, followed by once in four weeks. The pharmaceutical compositions to be administered may comprise about 1,200 mg of the anti-CD38 antibody and about 30,000 U of hyaluronidase, wherein the concentration of the antibody that specifically binds CD38 in the pharmaceutical composition is about 20 mg/ml. The pharmaceutical compositions to be administered may comprise about 1,800 mg of the anti-CD38 antibody and about 45,000 U of hyaluronidase. The pharmaceutical compositions to be administered may comprise about 1,600 mg of the anti-CD38 antibody and about 30,000 U of hyaluronidase. The pharmaceutical compositions to be administered may comprise about 1,600 mg of the anti-CD38 antibody and about 45,000 U of hyaluronidase.
The pharmaceutical composition comprising the anti-CD38 antibody and the hyaluronidase may be administered subcutaneously to the abdominal region.
The pharmaceutical composition comprising the anti-CD38 antibody and the hyaluronidase may be administered in a total volume of about 80 ml, 90 ml, 100 ml, 110 ml or 120 ml.
For administration, 20 mg/ml of the anti-CD38 antibody in 25 mM sodium acetate, 60 mM sodium chloride, 140 mM D-mannitol, 0.04% polysorbate 20, pH 5.5 may be mixed with rHuPH20, 1.0 mg/mL (75-150 kU/mL) in 10 mM L-Histidine, 130 mM NaCl, 10 mM L-Methionine, 0.02% Polysorbate 80, pH 6.5 prior to administration of the mixture to a subject. Further embodiments of the invention 1. An anti-CD38 antibody for use in treating a subject having a CD38-positive hematological malignancy, in combination with a survivin inhibitor.
2. A survivin inhibitor for use in treating a subject having a CD38-positive
hematological malignancy, in combination with an anti-CD38 antibody.
3. The combination of an anti-CD38 antibody and a survivin inhibitor for use in treating a subject having a CD38-positive hematological malignancy.
4. The anti-CD38 antibody for use according to embodiment 1, the survivin inhibitor for use according to embodiment 2, or the combination according to embodiment 3, wherein CD38-positive hematological malignancy is multiple myeloma (MM), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
5. The anti-CD38 antibody for use according to embodiment 1 or 4, the survivin inhibitor for use according to embodiment 2 or 4, or the combination according to embodiment 3 or 4, wherein CD38-positive hematological malignancy is a plasma cell disease.
6. The anti-CD38 antibody for use according to embodiment 1, 4 or 5, the survivin inhibitor for use according to embodiment 2, 4 or 5, or the combination according to embodiment 3, 4 or 5, wherein the plasma cell disease is light chain amyloidosis (AL), multiple myeloma (MM) or Waldenstrom’s
macroglobulinemia.
7. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-6, the survivin inhibitor for use according to any one of embodiments 2 or 4-6, or the combination according to any one of embodiments 3 or 4-6, wherein the plasma cell disease is MM.
8. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-7, the survivin inhibitor for use according to any one of embodiments 2 or 4-7, or the combination according to any one of embodiments 3 or 4-7, wherein the anti- CD38 antibody induces CD38-positive cell killing by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or apoptosis.
9. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-8, the survivin inhibitor for use according to any one of embodiments 2 or 4-8, or the combination according to any one of embodiments 3 or 4-8, wherein the anti- CD38 antibody is
a. of IgG1, IgG2, IgG3 or IgG4 isotype; or
b. is of IgG1 isotype.
10. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-9, the survivin inhibitor for use according to any one of embodiments 2 or 4-9, or the combination according to any one of embodiments 3 or 4-9, wherein the anti- CD38 antibody
a. competes for binding to CD38 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5;
b. binds to the region SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1);
c. comprises the heavy chain complementarity determining regions (HCDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) sequences of SEQ ID NOs: 6, 7 and 8, respectively;
d. comprises the light chain complementarity determining regions (LCDR) 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) sequences of SEQ ID NOs: 9, 10 and 11, respectively;
e. comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 sequences of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively;
f. comprises a heavy chain variable region (VH) comprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 4 and a light chain variable region (VL) omprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 5;
g. comprises the heavy chain variable region (VH) of SEQ ID NO: 4 and the light chain variable region (VL) of SEQ ID NO: 5; h. comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of:
i. the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 15;
ii. the VH of SEQ ID NO: 16 and the VL of SEQ ID NO: 17;
iii. the VH of SEQ ID NO: 18 and the VL of SEQ ID NO: 19; or iv. the VH of SEQ ID NO: 20 and the VL of SEQ ID NO: 21; or i. comprises:
i. the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 15;
ii. the VH of SEQ ID NO: 16 and the VL of SEQ ID NO: 17;
iii. the VH of SEQ ID NO: 18 and the VL of SEQ ID NO: 19; or iv. the VH of SEQ ID NO: 20 and the VL of SEQ ID NO: 21.
11. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-10, the survivin inhibitor for use according to any one of embodiments 2 or 4-10, or the combination according to any one of embodiments 3 or 4-10, wherein the anti- CD38 antibody comprises the heavy chain variable region (VH) of SEQ ID NO: 4 and the light chain variable region (VL) of SEQ ID NO: 5.
12. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-11, the survivin inhibitor for use according to any one of embodiments 2 or 4-11, or the combination according to any one of embodiments 3 or 4-11, wherein the survivin inhibitor is a small molecule, or a polynucleotide or a vaccine.
13. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-12, the survivin inhibitor for use according to any one of embodiments 2 or 4-12, or the combination according to any one of embodiments 3 or 4-12, wherein the survivin inhibitor is YM155.
14. The anti-CD38 antibody for use according to any one of embodiments 1 or 4-13, the survivin inhibitor for use according to any one of embodiments 2 or 4-13, or the combination according to any one of embodiments 3 or 4-13, wherein the anti- CD38 antibody and the survivin inhibitor are administered simultaneously, sequentially or separately.
15. An anti-CD38 antibody for use in treating a subject having a CD38-positive
hematological malignancy, in combination with a survivin inhibitor, wherein the anti-CD38 antibody comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 sequences of SEQ ID NOs: 6, 7, 8, 9, 10 and 11, respectively; 16. The anti-CD38 antibody for use according to embodiment 15, wherein the anti- CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5. 17. The anti-CD38 antibody for use according to embodiment 15 or 16, wherein the anti-CD38 antibody is of IgG1 isotype.
18. The anti-CD38 antibody for use according to any one of embodiments 15-17, wherein the anti-CD38 antibody comprises a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13.
19. The anti-CD38 antibody for use according to any one of embodiments 15-18, wherein the anti-CD38 antibody and the survivin inhibitor are administered simultaneously, sequentially or separately.
20. The anti-CD38 antibody for use according to any one of embodiments 15-19, wherein the anti-CD38 antibody is administered intravenously.
21. The anti-CD38 antibody for use according to any one of embodiments 15-19, wherein the anti-CD38 antibody is administered subcutaneously in a
pharmaceutical composition comprising the anti-CD38 antibody and a hyaluronidase.
22. The anti-CD38 antibody for use according to embodiment 21, wherein the
hyaluronidase is rHuPH20 of SEQ ID NO: 23.
23. The anti-CD38 antibody for use according to any one of embodiments 15-22, wherein the CD38-positive hematological malignancy is multiple myeloma. While having described the invention in general terms, the embodiments of the invention will be further disclosed in the following examples that should not be construed as limiting the scope of the claims. Materials and Methods Cells and Cell culture
Bone marrow mononuclear cells (BM-MNCs) and peripheral blood mononuclear cells (PBMCs)
BM aspirates from MM patients or healthy individuals, as well as PB from healthy individuals were collected using protocols and procedures approved by the institutional medical ethical committee in accordance with the declaration of Helsinki. Healthy Donor (HD)-PBMCs and BM-MNCs were isolated by Ficoll-Hypaque density-gradient centrifugation from PB samples or BM aspirates respectively. PBMCs were used directly as effector cells in ADCC experiments; BM-MNCs were cryopreserved until use. Multiple Myeloma (MM) cell lines
The luciferase (Luc)-transduced human MM cell lines RPMI-8226 and UM9 were maintained in RPMI1640 (Invitrogen), supplemented with 10% fetal bovine serum (FBS; Integro BV) and antibiotics (penicillin/streptomycin; Life Technologies) at 37°C in a humidified atmosphere containing 5% CO2. Bone marrow stromal cells (BMSC)
Adherent stromal cells were isolated and cultured from BM-MNCs of healthy individuals (hBMSC) or of MM patients (pBMSC) by plastic adherence. Cells were cultured in Optimem (Invitrogen) with 5% platelet lysate, heparin and antibiotics.
hBMSCs were used in experiments until passage six and pBMSC were used after passage one or two. Reagents
YM155 (Sepantronium Bromide; 4,9-Dihydro-1-(2-methoxyethyl)-2-methyl-4,9- dioxo-3-(2-pyrazinylmethyl)-1H-naphth[2,3-d]imidazolium bromide; CAS 781661-94-7) (Selleck Chemicals) was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1mM and aliquoted for storage until use. YM155 was diluted in culture medium to the concentrations indicated in each experiment. YM155; Formula I:
Figure imgf000039_0001
Compartment specific bioluminescence based Antibody dependent cell-mediated cytotoxicity (ADCC) against Multiple Myeloma cell lines (“compartment-specific BLI-based cytotoxicity assays”)
hBMSC were plated at a density of 1x104 cells/well in white opaque flat-bottomed 96-well plates (Costar) in 100μl culture medium. After an adherence period of six hours, luc-transduced MM cell lines were added at a density of 1x104 cells/well in BMSC-coated or uncoated wells. In experiments in which YM155 was tested, YM155 was added at indicated concentrations together with MM cells. After 16-20 hours, daratumumab was added at indicated concentrations and left for 15 minutes at room temperature. Freshly isolated PBMC from healthy individuals were then added as effector cells at the indicated effector target ratios. 4 hours after addition of PBMC, 125 ^g/ml beetle luciferin (Promega) was added and the bioluminescent signal emitted from surviving MM cells was determined within 20 minutes using a luminometer (SpectraMax, Molecular Devices). The percentage survival of MM cells was calculated using the formula: % survival = (mean bioluminescent signal in the absence of PBMCs / mean bioluminescent signal in the presence of PBMCs) x100%. In these assays the survival of MM cells is a direct reflection of ADCC mediated lysis and correlates with classical chromium release assays as described in McMillin et al., Nat Med 16:483-489, 2010. FACS based ADCC assay in Multiple Myeloma BM-MNC
Frozen BM-MNCs from MM patients with 15-35% CD138+ MM cells were used in FACS-based ADCC assays. The cells were thawed and cultured in 10% HS in RPMI. After 16-20 h, BM-MNCs were counted by trypan blue exclusion and 4x104 cells/well were plated in 96 round bottom plates. Daratumumab and/or YM155 were added in the wells as indicated per experiment. After 24 hours, cells were stained with fluorescent conjugated anti-CD138, anti-CD38, anti-CD56 and anti-CD3 antibodies and the survival of primary CD138+ MM cells in the BM-MNCs was determined by FACS as previously described (Groen et al., Blood 120:e9-e16, 2012). Percentage lysis of MM cells was deduced using the following formula: % lysis cells = 1- (counts of surviving CD138+ cells in treated wells/counts of number of surviving CD138+ cells in control wells) x 100%. Flow cytometry To determine the level of CD38 expression on MM cells, MM cells were cultured alone or with BMSCs and incubated with CD38 fluorescein conjugated antibody. The cells were additionally stained with CD105 as a marker for BMSCs. The CD38 expression on CD105 negative cells was determined by FACS as described (de Haart et al., Clin Cancer Res 19:5591-601, 2013). In vivo tumor targeting experiments Hybrid scaffolds consisting of three 2- to 3-mm biphasic calcium phosphate particles coated with HD-BMSC were in vitro loaded with Luc+ MM cell line UM9 (1x106 cells /scaffold) before s.c. implantation into RAG2-/-Ȗc-/- mice as described previously (Groen et al., Blood 120:e9-e16, 2012). Ten days after implantation, mice with tumors growing in the scaffolds were treated with vehicle control, daratumumab + PBS or daratumumab+ YM155. Each mice, including the control group, received in addition T cell-depleted HD-PBMCs (5x106 cells) as a source of human NK cells to induce ADCC. PBS and YM155-diluted in PBS were administered using ssubcutaneous infusion pumps (Alzet 1007D) delivering 1 mg/kg/d of the drug continuously. Pumps were removed after 10 days. BLI was performed as described previously (Spaapen et al., Clin Cancer Res 16:5481-88, 2010; Rozemuller et al., Haematologica 93:1049-57, 2008). Granzyme B Enzyme linked immunosorbent assay (ELISA) The granzyme B (GzB) content of cell-free supernatants was determined using a commercial ELISA kit (Pelipair, Sanquin, Amsterdam, NL) according to the
manufacturer’s instructions. Example 1. Bone Marrow stromal cells confer protection against antibody- dependent cellular cytotoxicity of multiple myeloma cells
Since the stromal cells of bone marrow (BM) microenvironment protect MM cells against CTL and NK mediated cytotoxicity, it was evaluated whether a similar protective effect occurs against antibody-dependent cellular cytotoxicity (ADCC) induced by daratumumab. Induction of ADCC by healthy donor BMSCs against two CD38+ luciferase transduced MM cell lines, UM9 and RPMI was tested with serial concentrations of daratumumab in the presence or absence of HD-PBMCs as effector cells in compartment- specific BLI-based cytotoxicity assays. In the absence of BMSCs, daratumumab mediated ADCC in both MM cell lines in a dose dependent fashion. Both cell lines were less sensitive to daratumumab-induced ADCC in the presence of BMSCs. Figure 1A shows the effect of BMSCs on daratumumab-induced ADCC in UM9 cells, and Figure 1B shows the effect of BMSCs on daratumumab-induced ADCC in RPMI-8226 cells.
Ability of BMSCs to protect primary MM cells from daratumumab-induced ADCC was also evaluated in a FACS-based ADCC assay using methodology described above. In the assays, BM-MNCs containing at least 15% CD138+ malignant plasma cells and sufficient numbers of autologous effector NK cells were incubated with daratumumab to induce ADCC. The BM-MNCs were tested either alone or in co-culture with autologous BMSCs to evaluate the effect of BMSCs. FACS-based viability assay was performed after 24 hours of culture to determine CD138+ surviving cells and calculate lysis. Induction of ADCC of primary MM cells was less efficient in the presence of autologous MM-BMSCs in both donors tested (Figure 2A and Figure 2B), indicating that the stromal cells of the tumor microenvironment induced a resistance to daratumumab therapy. Example 2. BMSC-induced suppression of ADCC is not caused by CD38 down- regulation or NK cell suppression.
Possible changes in CD38 surface expression and NK cell activation were evaluated to understand the mechanisms of BMSC-mediated protection against ADCC.
MM cell lines UM9 and RPMI-8226 were cultured in the presence or absence of healthy donor BMSCs. Co-culture of MM cells with BMSCs did not down-regulate the CD38 expression levels on either MM cell line (data not shown).
Since BMSCs are known to produce several immunosuppressive factors such as IDO, TGF-ȕ or PGE-2, the protection against ADCC by BMSCs could be due to the suppression of NK-cell activation, which would reduce their ability to degranulate and release granzyme B and perforin in the immune synapses to kill their targets. To that end, effect of BMSCs on NK cell activation by daratumumab was determined using daratumumab-mediated granzyme B excretion as a marker for NK cell activity. Granzyme B levels were in general higher in the supernatants in the presence pf BMSCs (data not shown). Hence, BMSC-mediated protection against ADCC was likely not due to NK cell suppression. Example 3. Survivin inhibition abrogates BMSC-mediated protection against ADCC and provides synergistic ADCC-mediated killing of multiple myeloma cells with daratumumab
BMSCs have been shown to protect MM cells against CTL lysis by up-regulation of survivin in MM cells. Modulation of survivin was evaluated as a possible mechanism for BMSC-mediated protection against ADCC induced by daratumumab using YM155, a small molecule inhibitor of survivin.
Effect of YM155 on NK cell viability was evaluated first. BM-MNCs of MM patients were cultured in the presence of different doses of YM155 for 24 hours. Viability of MM cells (CD138+ cells) and NK cells (CD3-CD138-CD56+ cells) were determined by FACS. NK cells were not affected at YM155 doses which already showed some toxicity to MM cells (Figure 3).
Effect of daratumumab, YM155, or a combination of daratumumab and YM155 was evaluated in RPMI-8226 cells and in two MM patient samples using YM155 concentrations shown to be non-toxic to NK cells.
In the assays, daratumumab and YM155 were used at a concentration of 0.3 μg/ml and 1 nM, respectively, for RPMI-8226 cells and at a concentration of 1 μg/ml and 120 nM for MM patient samples, respectively. Healthy donor PBMCs were used as effector cells at effector:target cell ratio of 40:1 for RPMI-8226 cells and 30:1 for MM patient samples.
In RPMI-8226 cells, daratumumab alone or YM155 alone induced lysis of about 20% of cells in the absence of BMSCs. In the presence of BMSCs, daratumumab induced lysis of about 10% of cells, whereas YM155 had no effect. Combination of daratumumab and YM155 provided a synergistic effect inducing lysis of about 50% of cells in the absence of BMSCs, and inducing lysis of about 45% of cells in the presence of BMSCs (Figure 4A). The synergistic effect of the combination of daratumumab and YM155 in the BMSCs was about 5-fold. Similarily, the combination of daratumumab and YM155 provided a synergistic effect in the MM patient sample 1 using 120 nM YM155 (Figure 4B), a moderate synergistic effect in the MM patient sample 2 using a lower amount of YM155 (64 nM) (Figure 4C), and in a combined sample of MM cells derived from 4 patients (Figure 4D). YM155 therefore abrogated the protective effects of BMSCs on daratumumab-mediated ADCC in MM cells and cell lines. Thus, survivin up-regulation may be an important mechanism of suppression of ADCC-mediated killing of MM cells, which can be prevented by pharmacological modulation of survivin. Example 4. In vivo antitumor effect of daratumumab and YM155 combination therapy
The in vivo relevance of the combination of daratumumab with YM155 was tested in the preclinical xenograft model in RAG2-/-gc-/- mice, in which MM tumors were grown in a humanized BM-like niche created by subcutaneous implantation of ceramic scaffolds coated with human BMSCs. Hybrid scaffolds coated with human MSCs and loaded with luciferase transduced MM cell line UM9 were implanted subcutaneously on the back of RAG2í/íȖcí/í mice (4 scaffolds per mice). Ten days after implantation, the growing tumors were visualized and quantified by BLI. Different groups of mice (n=4) were then either treated with vehicle control (control) or treated with daratumumab, YM155 or daratumumab plus YM155. YM155 or its vehicle, PBS was delivered with subcutaneous infusion pumps at a rate of 1 mg/kg/d YM155 for 10 days. Each mouse, including the control group, received T cell-depleted HD-PBMCs (5x106 cells) as a source of human NK cells to induce ADCC. Mice were monitored weekly by BLI. Figure 5 shows the relative tumor growth for each group. Statistical differences between mice treated with daratumumab and mice treated with daratumumab plus YM155 were calculated using the Mann-Whitney U-test. Daratumumab had a marginal effect on tumor growth. The anti- MM effect was more pronounced with YM155, which furthermore showed strong synergism with daratumumab to achieve significantly improved anti-MM effects. These results suggested that a clinical benefit may be expected from the combination of daratumumab with the survivin inhibitor YM155. The results presented demonstrate that suppressing survivin levels with a small molecule YM155 not only improved daratumumab-mediated ADCC in the absence of BMSCs, but importantly abrogated the ADCC resistance induced by BMSCs.
The addition of YM155 to daratumumab demonstrated enhanced antitumor effects also in the absence of BMSCs, which suggest the potential benefits of YM155-daratumumab combination therapy even if the MM cells are not in direct contact with BMSCs, such as in plasma cell leukemia. Moreover, the significant improvement of ADCC, up to a four-fold improvement of MM cell lysis, in the presence of BMSCs, suggests that a larger benefit from combining daratumumab therapy with YM155 can be achieved for MM cells which reside in the BM. It was also demonstrated that YM155 treatment does not negatively interfere with NK cell functions or viability, which is a prerequisite to consider clinical application of this combination therapy.
The efficacy of daratumumab in combination with YM155 was demonstrated in multiple myeloma, however, it can be extrapolated that the combination therapy may also be beneficial for other hematological tumors that express CD38, especially for those that mainly reside in the BM. In this respect AML is an eminent candidate, since AML cells not only express high levels of CD38, but also high levels of survivin, which is a predictor for poor clinical outcome. Another potential candidate for combination therapy might be CLL, since CLL cells have high survivin expression in the BM and CD38 is expressed in some patients. High CD38 and survivin expression in about 50% of non-Hodgkin lymphomas, makes this disease also relevant for evaluation of the efficacy of YM155- daratumumab combination. Altogether, a combination of daratumumab and YM155 may be broadly applicable for a wide range of hematological tumors.

Claims

We claim:
1. A method of treating a subject having a CD38-positive hematological malignancy, comprising administering to the subject in need thereof an anti-CD38 antibody and a survivin inhibitor for a time sufficient to treat the CD38-positive hematological malignancy.
2. The method of claim 1, wherein the CD38-positive hematological malignancy is multiple myeloma (MM), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt’s lymphoma (BL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
3. The method of claim 1, wherein the CD38-positive hematological malignancy is a plasma cell disease.
4. The method of claim 3, wherein the plasma cell disease is light chain amyloidosis (AL), multiple myeloma (MM) or Waldenstrom’s macroglobulinemia.
5. The method of claim 4, wherein the plasma cell disease is MM.
6. The method of any of the claims 1-5, wherein the anti-CD38 antibody competes for binding to CD38 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5.
7. The method of claim 6, wherein the anti-CD38 antibody binds to the region
SKRNIQFSCKNIYR (SEQ ID NO: 2) and the region EKVQTLEAWVIHGG (SEQ ID NO: 3) of human CD38 (SEQ ID NO: 1).
8. The method of claim 7, wherein the anti-CD38 antibody comprises a heavy chain complementarity determining region (HCDR) 1, a HCDR2 and a HCDR3 sequences of SEQ ID NOs: 6, 7 and 8, respectively, and a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 sequences of SEQ ID NOs: 9, 10 and 11, respectively.
9. The method of claim 8, wherein the anti-CD38 antibody comprises the VH
comprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 4 and the VL comprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 5.
10. The method claim 9, wherein the anti-CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5.
11. The method of claim 10, wherein the anti-CD38 antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.
12. The method of claim 11, wherein the anti-CD38 antibody is of IgG1 isotype.
13. The method of claim 12, wherein the anti-CD38 antibody induces CD38-positive cell killing by antibody-dependent cellular cytotoxicity (ADCC), antibody- dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or apoptosis.
14. The method of claim 1 or 3, wherein the anti-CD38 antibody comprises the
HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of: a. the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 15;
b. the VH of SEQ ID NO: 16 and the VL of SEQ ID NO: 17;
c. the VH of SEQ ID NO: 18 and the VL of SEQ ID NO: 19; or d. the VH of SEQ ID NO: 20 and the VL of SEQ ID NO: 21.
15. The method of claim 14, wherein the anti-CD38 antibody comprises:
a. the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 15;
b. the VH of SEQ ID NO: 16 and the VL of SEQ ID NO: 17;
c. the VH of SEQ ID NO: 18 and the VL of SEQ ID NO: 19; or d. the VH of SEQ ID NO: 20 and the VL of SEQ ID NO: 21.
16. The method of claim 1, wherein the survivin inhibitor is a small molecule, a polynucleotide or a vaccine.
17. The method of claim 16, wherein the small molecule is YM155.
18. The method of claim 1, wherein the anti-CD38 antibody and the survivin inhibitor are administered simultaneously, sequentially or separately.
19. The method of claim 18, wherein the anti-CD38 antibody is administered
intravenously.
20. The method of claim 18, wherein the anti-CD38 antibody is administered
subcutaneously in a pharmaceutical composition comprising the anti-CD38 antibody and a hyaluronidase.
21. The method of claim 20, wherein the hyaluronidase is rHuPH20 of SEQ ID NO:
23.
PCT/US2016/038702 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors Ceased WO2016209921A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
PH1/2017/502342A PH12017502342B1 (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
EA201890093A EA036789B1 (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
MYPI2017704912A MY192978A (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
UAA201800576A UA125115C2 (en) 2015-06-22 2016-06-22 Method of treating a subject having a multiple mieloma (mm)
ES16815196T ES2890783T3 (en) 2015-06-22 2016-06-22 Combination therapies for hematologic malignancies with anti-CD38 antibodies and survivin inhibitors
HK18110269.3A HK1250666B (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
NZ738208A NZ738208B2 (en) 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
IL256242A IL256242B2 (en) 2015-06-22 2016-06-22 Combination therapies for HEME malignancies with anti-CD38 antibodies and sorbibin inhibitors
CR20170587A CR20170587A (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
EP16815196.7A EP3310386B1 (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
CA2990406A CA2990406A1 (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
JP2017566284A JP6816038B2 (en) 2015-06-22 2016-06-22 Combination therapy for hematological malignancies with anti-CD38 antibody and survivin inhibitor
MX2018000265A MX391068B (en) 2015-06-22 2016-06-22 COMBINATION THERAPIES FOR HEMATOLOGICAL MALIGNANCIES WITH ANTI-CD38 ANTIBODIES AND SURVIVIN INHIBITORS.
CN201680037051.9A CN107708734B (en) 2015-06-22 2016-06-22 Combination therapy of heme malignancies with anti-CD 38 antibodies and survivin inhibitors
AU2016282674A AU2016282674B2 (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
KR1020187001610A KR102601550B1 (en) 2015-06-22 2016-06-22 Combination therapy for heme malignancies using anti-CD38 antibodies and survivin inhibitors
BR112017027724A BR112017027724A2 (en) 2015-06-22 2016-06-22 Combination therapies for hematological malignancies with anti-cd38 antibodies and survivin inhibitors
HK18110389.8A HK1250928B (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
TW105134915A TWI724046B (en) 2016-04-06 2016-10-28 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
CONC2017/0013331A CO2017013331A2 (en) 2015-06-22 2017-12-22 Combination therapies for hematologic malignancies with anti-cd38 antibodies and survivin inhibitors
ZA2018/00403A ZA201800403B (en) 2015-06-22 2018-01-19 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562182699P 2015-06-22 2015-06-22
US62/182,699 2015-06-22
US201662319036P 2016-04-06 2016-04-06
US62/319,036 2016-04-06

Publications (1)

Publication Number Publication Date
WO2016209921A1 true WO2016209921A1 (en) 2016-12-29

Family

ID=57585456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/038702 Ceased WO2016209921A1 (en) 2015-06-22 2016-06-22 Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors

Country Status (28)

Country Link
US (1) US10668149B2 (en)
EP (1) EP3310386B1 (en)
JP (1) JP6816038B2 (en)
KR (1) KR102601550B1 (en)
CN (1) CN107708734B (en)
AU (1) AU2016282674B2 (en)
BR (1) BR112017027724A2 (en)
CA (1) CA2990406A1 (en)
CL (1) CL2017003255A1 (en)
CO (1) CO2017013331A2 (en)
CR (1) CR20170587A (en)
DO (1) DOP2018000181A (en)
EA (1) EA036789B1 (en)
EC (1) ECSP17084270A (en)
ES (1) ES2890783T3 (en)
GT (1) GT201700284A (en)
IL (1) IL256242B2 (en)
MA (1) MA46315A (en)
MX (1) MX391068B (en)
MY (1) MY192978A (en)
NI (1) NI201700167A (en)
NZ (1) NZ777133A (en)
PE (1) PE20181323A1 (en)
PH (1) PH12017502342B1 (en)
SV (1) SV2017005606A (en)
UA (1) UA125115C2 (en)
WO (1) WO2016209921A1 (en)
ZA (1) ZA201800403B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3370770A4 (en) * 2015-11-03 2019-06-12 Janssen Biotech, Inc. SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND USES THEREOF
US10556961B2 (en) 2014-02-28 2020-02-11 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10604580B2 (en) 2014-09-09 2020-03-31 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US10766965B2 (en) 2015-05-20 2020-09-08 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US10793630B2 (en) 2014-12-04 2020-10-06 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
US10800851B2 (en) 2014-02-28 2020-10-13 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11021543B2 (en) 2015-06-24 2021-06-01 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US11685777B2 (en) 2016-07-20 2023-06-27 Janssen Pharmaceutica Nv Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
US12528878B2 (en) 2016-06-28 2026-01-20 Umc Utrecht Holding B.V. Treatment of IgE-mediated diseases with antibodies that specifically bind CD38

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5225069B2 (en) * 2005-03-23 2013-07-03 ゲンマブ エー／エス Antibodies against CD38 for the treatment of multiple myeloma
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SMT202000031T1 (en) 2010-06-09 2020-03-13 Genmab As ANTIBODIES AGAINST HUMAN CD38
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3109605A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CN111303293B (en) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 Fusion protein and application thereof
JP7712206B2 (en) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー Methods for treating multiple myeloma
WO2021155581A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating b-cell lymphomas
CN111808193B (en) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 Nanobody capable of binding human CD38 and its application

Citations (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1998044001A1 (en) 1997-03-27 1998-10-08 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO2001057059A1 (en) 2000-02-02 2001-08-09 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
WO2001060803A1 (en) 2000-02-15 2001-08-23 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazolium derivatives
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
WO2004092160A1 (en) 2003-04-15 2004-10-28 Astellas Pharma Inc. Bromide and its crystal
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
WO2005103083A2 (en) 2004-02-06 2005-11-03 Morphosys Ag Anti-cd38 human antibodies and uses therefor
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
WO2007042309A2 (en) 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
US20070287170A1 (en) 2006-03-24 2007-12-13 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
WO2008047242A2 (en) 2006-10-19 2008-04-24 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
WO2008077546A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
WO2009044793A1 (en) 2007-10-02 2009-04-09 Alphagen Co., Ltd. siRNA TARGETING ONCOGENE
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2009114476A1 (en) 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising survivin sirna and methods of use thereof
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
US7695936B2 (en) 1995-03-01 2010-04-13 Genentech, Inc. Knobs and holes heteromeric polypeptides
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20100286374A1 (en) 2008-01-07 2010-11-11 Gunasekaran Kannan Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20110123532A1 (en) 2009-04-27 2011-05-26 Oncomed Pharmaceuticals, Inc. Method for Making Heteromultimeric Molecules
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
WO2012022811A1 (en) 2010-08-20 2012-02-23 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen xv trimerization domain
US20120122910A1 (en) 2009-01-19 2012-05-17 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
WO2012092612A1 (en) 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
JPH06504186A (en) 1990-07-13 1994-05-19 ザ ジェネラル ホスピタル コーポレイション CD53 cell surface antigen and its uses
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1998016245A1 (en) 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Method of autoantibody assay
DK0932417T3 (en) 1996-10-17 2003-04-14 Immunomedics Inc Non-antigenic toxin conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
JP3835827B2 (en) 1997-05-02 2006-10-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Immunotoxin containing onc protein against malignant cells
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
JP2003535908A (en) 2000-06-22 2003-12-02 アイデック ファーマスーティカルズ コーポレイション Bispecific fusion proteins and methods of use to enhance effector cells that kill target cells
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
CA2424643A1 (en) 2000-10-17 2002-04-25 Trudeau Institute, Inc. Cd38 modulated chemotaxis
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
DE60317677T2 (en) 2002-06-13 2008-10-30 Crucell Holland B.V. OX40 (= CD134) RECEPTOR AGONISTS AND THERAPEUTIC USES
UA101945C2 (en) 2003-05-30 2013-05-27 Дженентек, Инк. Treatment of cancer using bevacizumab
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2542840A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
KR101128777B1 (en) 2003-11-04 2012-04-13 조마 테크놀로지 리미티드 Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US20090304687A1 (en) 2005-12-09 2009-12-10 Seattle Genetics , Inc. Methods of using cd40 binding agents
DK2049109T3 (en) 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
WO2008150530A2 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
MX2010005099A (en) 2007-11-09 2010-05-27 Novartis Ag Uses of anti-cd40 antibodies.
US8440199B2 (en) 2007-12-12 2013-05-14 Imperial Innovations Limited Methods for mobilizing mesenchymal stem cells in a patient
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
RU2589704C2 (en) 2008-03-25 2016-07-10 Роше Гликарт Аг Using anti-cd20 type ii antibody, having high antibody-induced cell-dependent cytotoxicity (adcc), combined with cyclophosphamide, vincristine and doxorubicin for treating non-hodgkin lymphomas
KR20130116386A (en) 2008-04-14 2013-10-23 할로자임, 아이엔씨 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
KR101695327B1 (en) 2008-11-07 2017-01-11 암젠 리서치 (뮌헨) 게엠베하 Treatment of Acute Lymphoblastic Leukemia
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
SMT202000092T1 (en) 2009-05-14 2020-05-08 Ambit Biosciences Corp Spray dried formulation of ac220
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
JP5898082B2 (en) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
US20130137134A1 (en) 2010-03-29 2013-05-30 Ben Gurion University Of The Negev Research And Development Authority Method and system for detecting and monitoring hematological cancer
DK2621531T3 (en) 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
KR20190120439A (en) * 2010-11-08 2019-10-23 제넨테크, 인크. Subcutaneously administered anti-il-6 receptor antibody
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
CL2013001944A1 (en) 2010-12-30 2014-09-12 Takeda Pharmaceutical Isolated antibody that specifically binds to human cd38 and cinomolgo cd38; nucleic acid encoding it; host cell; Method of production; and its use to treat an autoimmune disease.
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN108686203A (en) 2012-04-04 2018-10-23 哈洛齐梅公司 Use the combination treatment of anti-hyaluronic acid agent and cancer target taxane
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
MX368288B (en) 2012-09-25 2019-09-27 Morphosys Ag Combinations and uses thereof.
DK2914302T3 (en) 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
UA118255C2 (en) 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
WO2014142220A1 (en) 2013-03-13 2014-09-18 アステラス製薬株式会社 Anti-tumor agent
US20140271644A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
BR112015027313A2 (en) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anti-cd38 antibodies and attenuated interferon alfa-2b fusions
US20140356318A1 (en) 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
EP3021866A4 (en) 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Medical uses of cd38 agonists
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
EP3066125A2 (en) 2013-11-06 2016-09-14 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
EP3154581B1 (en) 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CN107406506A (en) 2014-12-04 2017-11-28 詹森生物科技公司 Anti-CD38 antibodies for the treatment of acute myeloid leukemia
EA201792546A1 (en) 2015-05-20 2018-04-30 Янссен Байотек, Инк. ANTIBODIES TO CD38 FOR THE TREATMENT OF AMYLOIDOSIS OF LUNG CHAINS AND OTHER CD38-POSITIVE HEMATOLOGICAL MALIGNANT TUMORS
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for HEME malignancies with anti-CD38 antibodies and sorbibin inhibitors
EA037548B1 (en) 2015-06-24 2021-04-12 Янссен Байотек, Инк. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS

Patent Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5403484A (en) 1988-09-02 1995-04-04 Protein Engineering Corporation Viruses expressing chimeric binding proteins
US5571698A (en) 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5580717A (en) 1990-05-01 1996-12-03 Affymax Technologies N.V. Recombinant library screening methods
US5969108A (en) 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6521404B1 (en) 1991-12-02 2003-02-18 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6544731B1 (en) 1991-12-02 2003-04-08 Medical Research Council Production of anti-self antibodies from antibody segment repertories and displayed on phage
US6555313B1 (en) 1991-12-02 2003-04-29 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6582915B1 (en) 1991-12-02 2003-06-24 Medical Research Council Production of anti-self bodies from antibody segment repertories and displayed on phage
US6593081B1 (en) 1991-12-02 2003-07-15 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US7695936B2 (en) 1995-03-01 2010-04-13 Genentech, Inc. Knobs and holes heteromeric polypeptides
WO1998044001A1 (en) 1997-03-27 1998-10-08 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2001057059A1 (en) 2000-02-02 2001-08-09 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
WO2001060803A1 (en) 2000-02-15 2001-08-23 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazolium derivatives
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040268425A1 (en) * 2003-03-05 2004-12-30 Deliatroph Pharmaceuticals, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
WO2004092160A1 (en) 2003-04-15 2004-10-28 Astellas Pharma Inc. Bromide and its crystal
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
WO2005103083A2 (en) 2004-02-06 2005-11-03 Morphosys Ag Anti-cd38 human antibodies and uses therefor
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
WO2007042309A2 (en) 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
US8088896B2 (en) 2005-10-12 2012-01-03 Morphosys Ag Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
US20070287170A1 (en) 2006-03-24 2007-12-13 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
WO2008047242A2 (en) 2006-10-19 2008-04-24 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
US8153765B2 (en) 2006-10-19 2012-04-10 Sanof Aventis Anti-CD38 antibodies for the treatment of cancer
WO2008077546A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
WO2009044793A1 (en) 2007-10-02 2009-04-09 Alphagen Co., Ltd. siRNA TARGETING ONCOGENE
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US20100286374A1 (en) 2008-01-07 2010-11-11 Gunasekaran Kannan Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009114476A1 (en) 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising survivin sirna and methods of use thereof
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US20120122910A1 (en) 2009-01-19 2012-05-17 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
US20110123532A1 (en) 2009-04-27 2011-05-26 Oncomed Pharmaceuticals, Inc. Method for Making Heteromultimeric Molecules
WO2011131746A2 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
WO2012022811A1 (en) 2010-08-20 2012-02-23 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen xv trimerization domain
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
WO2012092612A1 (en) 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies
US20140155584A1 (en) * 2010-12-30 2014-06-05 Takeda Pharmaceutical Company Limited Conjugated anti-cd38 antibodies

Non-Patent Citations (43)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2006, LIPINCOTT WILLIAMS AND WILKINS, article "Pharmaceutical Manufacturing", pages: 691 - 1092
ABDI ET AL., ONCOTARGET, vol. 4, 2013, pages 2186 - 2207
AL-LAZIKANI ET AL., J MOL BIOL, vol. 273, 1997, pages 927 - 48
ALMAGRO, MOL RECOGNIT, vol. 17, 2004, pages 132 - 43
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 781661-94-7
CHOTHIALESK, MOL BIOL, vol. 196, 1987, pages 901 - 17
DE HAART ET AL., CLIN CANCE RES, vol. 19, 2013, pages 5591 - 5601
DE HAART ET AL., CLIN CANCER RES, vol. 19, 2013, pages 5591 - 601
DE WEERS ET AL., JOURNAL OF IMMUNOLOGY, vol. 186, no. 3, 2010, pages 1840 - 1848
FERRARA ET AL., BIOTECHNOL BIOENG, vol. 93, 2006, pages 851 - 861
FERRARA ET AL., J BIOL CHEM, vol. 281, 2006, pages 5032 - 5036
GROEN ET AL., BLOOD, vol. 120, 2012, pages e9 - e16
HOOGENBOOMWINTER, J MOL BIOL, vol. 222, 1991, pages 581
KITA ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 343, no. 1, 2012, pages 178 - 183
KNAPPIK ET AL., J MOL BIOL, vol. 296, 2000, pages 57 - 86
KONNO ET AL., CYTOTECHNOLOGY, vol. 64, 2012, pages 249 - 65
KREBS ET AL., J IMMUNOL METH, vol. 254, 2001, pages 67 - 84
LEFRANC ET AL., DEV COMPARAT IMMUNOL, vol. 27, 2003, pages 55 - 77
LIU ET AL., CANCER BIOL. THER., vol. 7, 2008, pages 1053 - 1060
MACLENNAN ET AL., ACTA PHYSIOL SCAND SUPPL, vol. 643, 1988, pages 55 - 67
MACLENNAN ET AL., ACTA PHYSIOL SCAND SUPPL, vol. 643, 1998, pages 55 - 67
MANIER ET AL., J BIOMED BIOTECHNOL 2012, 3 October 2012 (2012-10-03)
MCMILLIN ET AL., NAT MED, vol. 16, 2010, pages 483 - 489
MITA ET AL., CLIN CANCER RES., vol. 14, 2008, pages 5000 - 5005
MORI ET AL., BIOTECHNOL BIOENG, vol. 88, 2004, pages 901 - 908
OLIVIER ET AL., MABS, vol. 2, no. 4, 2010
ROZEMULLER ET AL., HAEMATOLOGICA, vol. 93, 2008, pages 1049 - 57
SASAKI ET AL., ADV BIOPHYS, vol. 35, 1988, pages 1 - 24
SASAKI ET AL., ADV BIOPHYS, vol. 35, 1998, pages 1 - 24
SHEETS ET AL., PITAS (USA, vol. 95, 1998, pages 6157 - 6162
SHI ET AL., J MOL BIOL, vol. 397, 2010, pages 385 - 96
SHI ET AL., J. MOL. BIOL., vol. 397, 2010, pages 385 - 96
SHIELDS ET AL., J BIOL CHEM, vol. 277, 2002, pages 26733 - 26740
SHINKAWA ET AL., J BIOL CHEM, vol. 278, 2003, pages 3466 - 3473
SPAAPEN ET AL., CLIN CANCER RES, vol. 16, 2010, pages 5481 - 88
VAN DER VEER ET AL., BLOOD CANCER J, vol. 1, no. 10, 2011, pages e41
VAN DER VEER ET AL., HAEMATOLOGICA, vol. 96, 2011, pages 284 - 290
VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 309 - 314
WAGNER ET AL., ONCOTARGET, vol. 5, no. 21, 2014, pages 10237 - 10250
WAGNER ET AL.: "Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.", ONCOTARGET., vol. 5, no. 21, 15 November 2014 (2014-11-15), pages 10237 - 50, XP055341548 *
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WUKABAT, J EXP MED, vol. 132, 1970, pages 211 - 50
XHOU ET AL., BIOTECHNOL BIOENG, vol. 99, 2008, pages 652 - 65

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713355B2 (en) 2014-02-28 2023-08-01 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10556961B2 (en) 2014-02-28 2020-02-11 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10800851B2 (en) 2014-02-28 2020-10-13 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US12060432B2 (en) 2014-02-28 2024-08-13 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10604580B2 (en) 2014-09-09 2020-03-31 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US12286474B2 (en) 2014-12-04 2025-04-29 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
US10793630B2 (en) 2014-12-04 2020-10-06 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
US10766965B2 (en) 2015-05-20 2020-09-08 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
US12091466B2 (en) 2015-05-20 2024-09-17 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US11021543B2 (en) 2015-06-24 2021-06-01 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US10385135B2 (en) 2015-11-03 2019-08-20 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11566079B2 (en) 2015-11-03 2023-01-31 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US12583936B2 (en) 2015-11-03 2026-03-24 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP4085929A1 (en) * 2015-11-03 2022-11-09 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US11708419B2 (en) 2015-11-03 2023-07-25 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11708420B2 (en) 2015-11-03 2023-07-25 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3827845B1 (en) 2015-11-03 2022-03-30 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
AU2016350717B2 (en) * 2015-11-03 2023-08-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11732051B2 (en) 2015-11-03 2023-08-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3370770B1 (en) 2015-11-03 2021-01-20 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
EP3370770A4 (en) * 2015-11-03 2019-06-12 Janssen Biotech, Inc. SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND USES THEREOF
US12528878B2 (en) 2016-06-28 2026-01-20 Umc Utrecht Holding B.V. Treatment of IgE-mediated diseases with antibodies that specifically bind CD38
US11685777B2 (en) 2016-07-20 2023-06-27 Janssen Pharmaceutica Nv Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
US11884722B2 (en) 2016-07-20 2024-01-30 Janssen Biotech, Inc. Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Also Published As

Publication number Publication date
JP2018522857A (en) 2018-08-16
CN107708734A (en) 2018-02-16
GT201700284A (en) 2019-08-26
HK1250928A1 (en) 2019-01-18
EP3310386A4 (en) 2019-01-02
EP3310386A1 (en) 2018-04-25
AU2016282674A1 (en) 2018-01-18
NZ738208A (en) 2024-07-26
CL2017003255A1 (en) 2018-05-11
EP3310386B1 (en) 2021-07-21
PE20181323A1 (en) 2018-08-14
KR102601550B1 (en) 2023-11-10
IL256242A (en) 2018-02-28
IL256242B1 (en) 2024-05-01
AU2016282674B2 (en) 2022-01-13
MX391068B (en) 2025-03-21
CA2990406A1 (en) 2016-12-29
PH12017502342B1 (en) 2024-01-05
CR20170587A (en) 2018-04-03
UA125115C2 (en) 2022-01-12
MA46315A (en) 2019-08-07
PH12017502342A1 (en) 2018-07-02
JP6816038B2 (en) 2021-01-20
MY192978A (en) 2022-09-20
US10668149B2 (en) 2020-06-02
ZA201800403B (en) 2021-07-28
NI201700167A (en) 2018-08-01
MX2018000265A (en) 2018-05-23
SV2017005606A (en) 2018-06-26
BR112017027724A2 (en) 2019-01-08
CO2017013331A2 (en) 2018-05-21
US20160367663A1 (en) 2016-12-22
ECSP17084270A (en) 2018-02-28
HK1250666A1 (en) 2019-01-11
IL256242B2 (en) 2024-09-01
DOP2018000181A (en) 2019-03-15
EA201890093A1 (en) 2018-05-31
EA036789B1 (en) 2020-12-22
KR20180015258A (en) 2018-02-12
CN107708734B (en) 2022-01-11
ES2890783T3 (en) 2022-01-24
NZ777133A (en) 2025-05-02

Similar Documents

Publication Publication Date Title
EP3310386B1 (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20250011457A1 (en) Combination Therapies with Anti-CD38 Antibodies
US11713355B2 (en) Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10604580B2 (en) Combination therapies with anti-CD38 antibodies
TWI724046B (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
HK1250666B (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
HK1250928B (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
NZ723538B2 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16815196

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 11201710390V

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 12017502342

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2017-000167 I

Country of ref document: NI

Ref document number: CR2017-000587

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2990406

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017566284

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 002793-2017

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: NC2017/0013331

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/000265

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20187001610

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016282674

Country of ref document: AU

Date of ref document: 20160622

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201890093

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201800576

Country of ref document: UA

Ref document number: 2016815196

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017027724

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112017027724

Country of ref document: BR

Free format text: EXPLIQUE A DIVERGENCIA NO NOME DE UM DOS INVENTORES (PARUL DOSHI) QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2016/209921 E O CONSTANTE DA PETICAO INICIAL NO 870170100481

ENP Entry into the national phase

Ref document number: 112017027724

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171221